{
"company_details": [
{
"company_id": "0000885462",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000885462.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000885462.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000885462.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000885462_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000885462_main_keyfigs.svg",
"name": "GULF Resources INC",
"rank": 1,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000885462.svg",
"report_text": "The relative strengths and weaknesses of GULF Resources INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of GULF Resources INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points.The greatest weakness of GULF Resources INC is the variable Other Net Income, reducing the Economic Capital Ratio by 7.6% points.
The company's Economic Capital Ratio, given in the ranking table, is 287%, being 134% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000885462_2012_GULF_Resources_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "58.2",
"Liabilities": "78.6",
"Assets": "1.19",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "196",
"Liabilities, Non-Current": "18.5",
"Other Liabilities": "15.1",
"Property, Plant and Equipment, Net": "2.06",
"Assets, Non-Current": "2.81",
"Other Assets": "-0.918",
"General and Administrative Expense": "5.94",
"Expenses": "32.9",
"Revenues": "28.8",
"Net Income": "52.7",
"Research and Development": "15.6",
"Other Expenses": "12.3",
"Other Revenues": "28.8",
"Comprehensive Net Income": "55.8",
"Other Net Income": "-7.64",
"Other Compr. Net Income": "3.57",
"Economic Capital Ratio": "134"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000885462_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "105,517",
"Assets, Non-Current": "152,811",
"General and Administrative Expense": "107,413",
"Goodwill": "0",
"Liabilities, Current": "12,178",
"Liabilities, Non-Current": "0",
"Other Assets": "-147,201",
"Other Compr. Net Income": "12,493",
"Other Expenses": "26,274",
"Other Liabilities": "3,037",
"Other Net Income": "57",
"Other Revenues": "164,980",
"Property, Plant and Equipment, Net": "147,201",
"Research and Development": "399"
},
"output_variables": {
"Liabilities": "15,215",
"Assets": "258,328",
"Expenses": "134,085",
"Revenues": "164,980",
"Stockholders Equity": "243,113",
"Net Income": "30,953",
"Comprehensive Net Income": "37,199",
"BaseVar": "292,579",
"ECR before LimitedLiability": "271%",
"Economic Capital Ratio": "287%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.8732160862440677,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000885462.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000885462.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000885462.svg"
},
{
"company_id": "0000899923",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000899923.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000899923.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000899923_main_keyfigs.svg",
"name": "Myriad Genetics INC",
"rank": 2,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000899923.svg",
"report_text": "The relative strengths and weaknesses of Myriad Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Myriad Genetics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 106% points.The greatest weakness of Myriad Genetics INC is the variable Other Net Income, reducing the Economic Capital Ratio by 7.4% points.
The company's Economic Capital Ratio, given in the ranking table, is 285%, being 132% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000899923_2012_Myriad_Genetics_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "-1.22",
"Liabilities": "69.0",
"Stockholders Equity": "98.4",
"ECR before LimitedLiability": "125",
"Liabilities, Current": "33.4",
"Liabilities, Non-Current": "45.6",
"Goodwill": "1.45",
"Assets": "-6.03",
"Property, Plant and Equipment, Net": "1.03",
"Assets, Current": "-9.25",
"Assets, Non-Current": "-0.952",
"Other Expenses": "27.3",
"Expenses": "28.0",
"Revenues": "14.8",
"Net Income": "44.5",
"General and Administrative Expense": "-1.98",
"Research and Development": "2.70",
"Other Revenues": "14.8",
"Other Net Income": "3.09",
"Comprehensive Net Income": "44.6",
"Economic Capital Ratio": "127"
},
"2011": {
"Liabilities, Current": "53.8",
"Liabilities": "73.2",
"Stockholders Equity": "106",
"ECR before LimitedLiability": "194",
"Liabilities, Non-Current": "17.8",
"Other Liabilities": "13.0",
"Property, Plant and Equipment, Net": "-0.276",
"Assets": "2.26",
"Assets, Non-Current": "0.356",
"Other Assets": "0.209",
"Assets, Current": "1.57",
"General and Administrative Expense": "13.9",
"Expenses": "33.8",
"Revenues": "32.3",
"Net Income": "57.1",
"Research and Development": "8.82",
"Other Expenses": "12.1",
"Other Revenues": "32.3",
"Comprehensive Net Income": "57.0",
"Other Net Income": "-7.41",
"Economic Capital Ratio": "132"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000899923_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "473,976",
"Assets, Non-Current": "85,154",
"General and Administrative Expense": "205,700",
"Goodwill": "2,052",
"Liabilities, Current": "27,466",
"Liabilities, Non-Current": "0",
"Other Assets": "9,404",
"Other Compr. Net Income": "0",
"Other Expenses": "-11,469",
"Other Liabilities": "8,800",
"Other Net Income": "0",
"Other Revenues": "368,407",
"Property, Plant and Equipment, Net": "23,261",
"Research and Development": "21,873"
},
"output_variables": {
"Liabilities": "36,266",
"Assets": "593,847",
"Expenses": "216,104",
"Revenues": "368,407",
"Stockholders Equity": "557,581",
"Net Income": "152,303",
"Comprehensive Net Income": "152,303",
"BaseVar": "607,312",
"ECR before LimitedLiability": "291%",
"Economic Capital Ratio": "304%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "418,261",
"Assets, Non-Current": "70,857",
"General and Administrative Expense": "215,478",
"Goodwill": "72,766",
"Liabilities, Current": "34,387",
"Liabilities, Non-Current": "0",
"Other Assets": "25,863",
"Other Compr. Net Income": "0",
"Other Expenses": "60,018",
"Other Liabilities": "9,648",
"Other Net Income": "0",
"Other Revenues": "403,957",
"Property, Plant and Equipment, Net": "23,080",
"Research and Development": "27,751"
},
"output_variables": {
"Liabilities": "44,035",
"Assets": "610,827",
"Expenses": "303,247",
"Revenues": "403,957",
"Stockholders Equity": "566,792",
"Net Income": "100,710",
"Comprehensive Net Income": "100,710",
"BaseVar": "681,033",
"ECR before LimitedLiability": "268%",
"Economic Capital Ratio": "285%"
}
}
},
"top_rated": true,
"trend": -1.0,
"value": 2.8508023826683937,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000899923.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000899923.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000899923.svg"
},
{
"company_id": "0000794172",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000794172.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000794172.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000794172_main_keyfigs.svg",
"name": "Meridian Bioscience INC",
"rank": 3,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000794172.svg",
"report_text": "The relative strengths and weaknesses of Meridian Bioscience INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Meridian Bioscience INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 86% points.The greatest weakness of Meridian Bioscience INC is the variable Other Expenses, reducing the Economic Capital Ratio by 36% points.
The company's Economic Capital Ratio, given in the ranking table, is 276%, being 123% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000794172_2012_Meridian_Bioscience_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "1.55",
"Liabilities": "21.8",
"Stockholders Equity": "51.4",
"ECR before LimitedLiability": "62.8",
"Liabilities, Current": "18.5",
"Other Liabilities": "2.31",
"Property, Plant and Equipment, Net": "-0.449",
"Assets": "2.99",
"Other Assets": "-1.08",
"Assets, Current": "3.82",
"Assets, Non-Current": "0.609",
"Goodwill": "0.588",
"General and Administrative Expense": "29.9",
"Expenses": "20.1",
"Revenues": "-1.56",
"Net Income": "18.9",
"Other Expenses": "-6.87",
"Research and Development": "-3.78",
"Other Revenues": "-1.56",
"Comprehensive Net Income": "19.0",
"Economic Capital Ratio": "62.0"
},
"2010": {
"Other Liabilities": "6.11",
"Liabilities": "74.1",
"Stockholders Equity": "61.8",
"ECR before LimitedLiability": "99.5",
"Liabilities, Current": "29.2",
"Liabilities, Non-Current": "50.9",
"Goodwill": "0.732",
"Assets": "0.843",
"Assets, Current": "1.06",
"Assets, Non-Current": "1.69",
"Other Assets": "-1.80",
"Other Expenses": "-35.7",
"Expenses": "-1.55",
"Revenues": "29.3",
"Net Income": "31.7",
"General and Administrative Expense": "28.8",
"Research and Development": "2.56",
"Other Revenues": "29.3",
"Other Net Income": "4.05",
"Comprehensive Net Income": "31.8",
"Economic Capital Ratio": "101"
},
"2011": {
"Liabilities, Current": "58.6",
"Liabilities": "85.5",
"Stockholders Equity": "78.4",
"ECR before LimitedLiability": "185",
"Liabilities, Non-Current": "21.8",
"Other Liabilities": "22.8",
"Property, Plant and Equipment, Net": "0.429",
"Assets": "1.64",
"Assets, Non-Current": "2.86",
"Other Assets": "-2.25",
"Goodwill": "1.26",
"General and Administrative Expense": "39.3",
"Expenses": "17.5",
"Revenues": "58.2",
"Net Income": "65.8",
"Research and Development": "10.9",
"Other Expenses": "-36.3",
"Other Revenues": "58.2",
"Comprehensive Net Income": "65.8",
"Other Net Income": "-9.05",
"Economic Capital Ratio": "123"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000794172_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "117,147",
"Assets, Non-Current": "18,376",
"General and Administrative Expense": "35,576",
"Goodwill": "17,183",
"Liabilities, Current": "16,752",
"Liabilities, Non-Current": "0",
"Other Assets": "-17,183",
"Other Compr. Net Income": "0",
"Other Expenses": "72,055",
"Other Liabilities": "0",
"Other Net Income": "544",
"Other Revenues": "148,274",
"Property, Plant and Equipment, Net": "20,474",
"Research and Development": "8,428"
},
"output_variables": {
"Liabilities": "16,752",
"Assets": "155,997",
"Expenses": "116,059",
"Revenues": "148,274",
"Stockholders Equity": "139,245",
"Net Income": "32,759",
"Comprehensive Net Income": "32,759",
"BaseVar": "218,813",
"ECR before LimitedLiability": "259%",
"Economic Capital Ratio": "278%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "94,020",
"Assets, Non-Current": "38,048",
"General and Administrative Expense": "37,527",
"Goodwill": "36,809",
"Liabilities, Current": "14,147",
"Liabilities, Non-Current": "0",
"Other Assets": "-36,809",
"Other Compr. Net Income": "0",
"Other Expenses": "70,518",
"Other Liabilities": "0",
"Other Net Income": "262",
"Other Revenues": "143,000",
"Property, Plant and Equipment, Net": "22,717",
"Research and Development": "8,570"
},
"output_variables": {
"Liabilities": "14,147",
"Assets": "154,785",
"Expenses": "116,615",
"Revenues": "143,000",
"Stockholders Equity": "140,638",
"Net Income": "26,647",
"Comprehensive Net Income": "26,647",
"BaseVar": "214,404",
"ECR before LimitedLiability": "260%",
"Economic Capital Ratio": "279%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "90,354",
"Assets, Non-Current": "38,600",
"General and Administrative Expense": "47,655",
"Goodwill": "34,071",
"Liabilities, Current": "15,264",
"Liabilities, Non-Current": "0",
"Other Assets": "-34,071",
"Other Compr. Net Income": "0",
"Other Expenses": "75,882",
"Other Liabilities": "0",
"Other Net Income": "467",
"Other Revenues": "159,723",
"Property, Plant and Equipment, Net": "26,539",
"Research and Development": "9,822"
},
"output_variables": {
"Liabilities": "15,264",
"Assets": "155,493",
"Expenses": "133,359",
"Revenues": "159,723",
"Stockholders Equity": "140,229",
"Net Income": "26,831",
"Comprehensive Net Income": "26,831",
"BaseVar": "232,153",
"ECR before LimitedLiability": "256%",
"Economic Capital Ratio": "276%"
}
}
},
"top_rated": true,
"trend": -1.0,
"value": 2.7606705785307026,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000794172.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000794172.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000794172.svg"
},
{
"company_id": "0000736822",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000736822.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000736822.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000736822_main_keyfigs.svg",
"name": "Immucor INC",
"rank": 4,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000736822.svg",
"report_text": "The relative strengths and weaknesses of Immucor INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immucor INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Immucor INC is the variable Other Expenses, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 270%, being 117% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000736822_2012_Immucor_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "39.5",
"Liabilities": "54.4",
"Assets": "10.7",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "179",
"Liabilities, Non-Current": "13.7",
"Other Liabilities": "7.43",
"Assets, Non-Current": "-0.617",
"Goodwill": "2.94",
"Assets, Current": "6.71",
"General and Administrative Expense": "38.1",
"Expenses": "36.3",
"Revenues": "17.8",
"Net Income": "48.0",
"Research and Development": "9.70",
"Other Expenses": "-12.0",
"Other Revenues": "17.8",
"Comprehensive Net Income": "47.9",
"Other Net Income": "-5.26",
"Other Compr. Net Income": "-0.0529",
"Economic Capital Ratio": "117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000736822_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "425,889",
"Assets, Non-Current": "1,122",
"General and Administrative Expense": "74,178",
"Goodwill": "147,900",
"Liabilities, Current": "46,910",
"Liabilities, Non-Current": "2,001",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "158,319",
"Other Liabilities": "15,344",
"Other Net Income": "4,633",
"Other Revenues": "333,091",
"Property, Plant and Equipment, Net": "58,216",
"Research and Development": "15,900"
},
"output_variables": {
"Liabilities": "64,255",
"Assets": "633,127",
"Expenses": "248,397",
"Revenues": "333,091",
"Stockholders Equity": "568,872",
"Net Income": "89,327",
"Comprehensive Net Income": "89,327",
"BaseVar": "641,752",
"ECR before LimitedLiability": "249%",
"Economic Capital Ratio": "270%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.704342234133784,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000736822.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000736822.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000736822.svg"
},
{
"company_id": "0000787253",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000787253.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000787253.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000787253.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000787253_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000787253_main_keyfigs.svg",
"name": "Natural Alternatives International Inc",
"rank": 5,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000787253.svg",
"report_text": "The relative strengths and weaknesses of Natural Alternatives International Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Natural Alternatives International Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 89% points.The greatest weakness of Natural Alternatives International Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 107% points.
The company's Economic Capital Ratio, given in the ranking table, is 256%, being 102% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000787253_2012_Natural_Alternatives_International_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "62.5",
"Liabilities": "88.8",
"Stockholders Equity": "49.0",
"ECR before LimitedLiability": "164",
"Liabilities, Non-Current": "23.3",
"Other Liabilities": "19.7",
"Property, Plant and Equipment, Net": "3.33",
"Assets": "-2.70",
"Assets, Non-Current": "-1.64",
"Other Assets": "1.14",
"Goodwill": "-3.98",
"Assets, Current": "-0.823",
"Other Revenues": "75.4",
"Revenues": "75.4",
"Net Income": "65.3",
"General and Administrative Expense": "65.6",
"Comprehensive Net Income": "65.2",
"Research and Development": "22.0",
"Other Net Income": "-10.7",
"Other Expenses": "-107",
"Economic Capital Ratio": "102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000787253_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "27,828",
"Assets, Non-Current": "453",
"General and Administrative Expense": "8,304",
"Goodwill": "0",
"Liabilities, Current": "4,947",
"Liabilities, Non-Current": "0",
"Other Assets": "1,452",
"Other Compr. Net Income": "50",
"Other Expenses": "42,517",
"Other Liabilities": "719",
"Other Net Income": "25",
"Other Revenues": "55,882",
"Property, Plant and Equipment, Net": "11,411",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "5,666",
"Assets": "41,144",
"Expenses": "50,821",
"Revenues": "55,882",
"Stockholders Equity": "35,478",
"Net Income": "5,086",
"Comprehensive Net Income": "5,111",
"BaseVar": "76,794",
"ECR before LimitedLiability": "230%",
"Economic Capital Ratio": "256%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.5575838521949446,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000787253.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000787253.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000787253.svg"
},
{
"company_id": "0000711377",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000711377.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000711377.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000711377.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000711377_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000711377_main_keyfigs.svg",
"name": "Neogen CORP",
"rank": 6,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000711377.svg",
"report_text": "The relative strengths and weaknesses of Neogen CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Neogen CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 75% points.The greatest weakness of Neogen CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 253%, being 99% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000711377_2012_Neogen_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "46.8",
"Liabilities": "58.2",
"Stockholders Equity": "75.5",
"ECR before LimitedLiability": "161",
"Liabilities, Non-Current": "16.5",
"Property, Plant and Equipment, Net": "-0.558",
"Assets": "8.68",
"Assets, Non-Current": "11.8",
"Other Assets": "-6.01",
"Goodwill": "4.29",
"Assets, Current": "2.07",
"General and Administrative Expense": "38.8",
"Expenses": "22.5",
"Revenues": "33.8",
"Net Income": "48.0",
"Research and Development": "11.6",
"Other Expenses": "-30.7",
"Other Revenues": "33.8",
"Comprehensive Net Income": "48.3",
"Other Net Income": "-7.82",
"Economic Capital Ratio": "99.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000711377_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "122,502",
"Assets, Non-Current": "74,820",
"General and Administrative Expense": "45,132",
"Goodwill": "51,584",
"Liabilities, Current": "17,797",
"Liabilities, Non-Current": "0",
"Other Assets": "-51,584",
"Other Compr. Net Income": "1,282",
"Other Expenses": "97,291",
"Other Liabilities": "12,887",
"Other Net Income": "-596",
"Other Revenues": "172,683",
"Property, Plant and Equipment, Net": "22,340",
"Research and Development": "6,825"
},
"output_variables": {
"Liabilities": "30,684",
"Assets": "219,662",
"Expenses": "149,248",
"Revenues": "172,683",
"Stockholders Equity": "188,978",
"Net Income": "22,839",
"Comprehensive Net Income": "23,480",
"BaseVar": "287,078",
"ECR before LimitedLiability": "226%",
"Economic Capital Ratio": "253%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.529042075758659,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000711377.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000711377.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000711377.svg"
},
{
"company_id": "0000353569",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000353569.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000353569.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000353569_main_keyfigs.svg",
"name": "Quidel CORP DE",
"rank": 7,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000353569.svg",
"report_text": "The relative strengths and weaknesses of Quidel CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Quidel CORP DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 91% points.The greatest weakness of Quidel CORP DE is the variable Other Net Income, reducing the Economic Capital Ratio by 7.5% points.
The company's Economic Capital Ratio, given in the ranking table, is 250%, being 96% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000353569_2012_Quidel_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.4",
"Liabilities": "51.4",
"Stockholders Equity": "90.6",
"ECR before LimitedLiability": "158",
"Liabilities, Non-Current": "14.2",
"Other Liabilities": "14.9",
"Assets": "16.4",
"Assets, Non-Current": "-1.26",
"Other Assets": "0.0652",
"Goodwill": "22.7",
"Assets, Current": "-1.50",
"General and Administrative Expense": "6.18",
"Expenses": "25.0",
"Revenues": "17.0",
"Net Income": "34.4",
"Research and Development": "1.43",
"Other Expenses": "17.8",
"Other Revenues": "17.0",
"Comprehensive Net Income": "34.3",
"Other Net Income": "-7.48",
"Economic Capital Ratio": "96.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000353569_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "104,726",
"Assets, Non-Current": "1,239",
"General and Administrative Expense": "111,414",
"Goodwill": "144,843",
"Liabilities, Current": "32,926",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "10,975",
"Other Liabilities": "0",
"Other Net Income": "-2,256",
"Other Revenues": "158,603",
"Property, Plant and Equipment, Net": "28,086",
"Research and Development": "26,325"
},
"output_variables": {
"Liabilities": "32,926",
"Assets": "278,894",
"Expenses": "148,714",
"Revenues": "158,603",
"Stockholders Equity": "245,968",
"Net Income": "7,633",
"Comprehensive Net Income": "7,633",
"BaseVar": "310,696",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "250%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.4960810557049724,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000353569.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000353569.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000353569.svg"
},
{
"company_id": "0000768408",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000768408.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000768408.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000768408.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000768408_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000768408_main_keyfigs.svg",
"name": "Cyanotech CORP",
"rank": 8,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000768408.svg",
"report_text": "The relative strengths and weaknesses of Cyanotech CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cyanotech CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 65% points.The greatest weakness of Cyanotech CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 54% points.
The company's Economic Capital Ratio, given in the ranking table, is 238%, being 84% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000768408_2012_Cyanotech_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "44.2",
"Liabilities": "64.9",
"Stockholders Equity": "41.4",
"ECR before LimitedLiability": "146",
"Liabilities, Non-Current": "9.21",
"Other Liabilities": "19.9",
"General and Administrative Expense": "39.9",
"Expenses": "8.05",
"Net Income": "58.1",
"Research and Development": "16.6",
"Other Expenses": "-54.2",
"Other Revenues": "59.5",
"Revenues": "59.5",
"Property, Plant and Equipment, Net": "7.85",
"Assets, Non-Current": "-1.81",
"Other Assets": "1.74",
"Goodwill": "-5.37",
"Assets, Current": "-1.96",
"Comprehensive Net Income": "58.0",
"Other Net Income": "-9.70",
"Economic Capital Ratio": "84.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000768408_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,481",
"Assets, Non-Current": "287",
"General and Administrative Expense": "4,808",
"Goodwill": "0",
"Liabilities, Current": "2,196",
"Liabilities, Non-Current": "553",
"Other Assets": "535",
"Other Compr. Net Income": "0",
"Other Expenses": "9,941",
"Other Liabilities": "0",
"Other Net Income": "-66",
"Other Revenues": "16,827",
"Property, Plant and Equipment, Net": "4,557",
"Research and Development": "282"
},
"output_variables": {
"Liabilities": "2,749",
"Assets": "13,860",
"Expenses": "15,031",
"Revenues": "16,827",
"Stockholders Equity": "11,111",
"Net Income": "1,730",
"Comprehensive Net Income": "1,730",
"BaseVar": "24,266",
"ECR before LimitedLiability": "204%",
"Economic Capital Ratio": "238%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.376557848672678,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000768408.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000768408.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000768408.svg"
},
{
"company_id": "0000896264",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000896264.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000896264.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000896264.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000896264_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000896264_main_keyfigs.svg",
"name": "Usana Health Sciences INC",
"rank": 9,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000896264.svg",
"report_text": "The relative strengths and weaknesses of Usana Health Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Usana Health Sciences INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 150% points.The greatest weakness of Usana Health Sciences INC is the variable Other Expenses, reducing the Economic Capital Ratio by 152% points.
The company's Economic Capital Ratio, given in the ranking table, is 235%, being 81% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000896264_2012_Usana_Health_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "67.6",
"Liabilities": "107",
"Stockholders Equity": "-19.3",
"ECR before LimitedLiability": "143",
"Liabilities, Non-Current": "28.7",
"Other Liabilities": "30.0",
"Property, Plant and Equipment, Net": "-0.726",
"Assets": "-19.1",
"Assets, Non-Current": "-3.29",
"Other Assets": "2.14",
"Assets, Current": "-18.2",
"General and Administrative Expense": "65.1",
"Expenses": "-30.3",
"Revenues": "150",
"Net Income": "95.7",
"Research and Development": "29.6",
"Other Expenses": "-152",
"Other Revenues": "150",
"Comprehensive Net Income": "95.6",
"Other Net Income": "-14.5",
"Economic Capital Ratio": "81.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000896264_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "106,059",
"Assets, Non-Current": "6,273",
"General and Administrative Expense": "137,063",
"Goodwill": "60,377",
"Liabilities, Current": "59,696",
"Liabilities, Non-Current": "0",
"Other Assets": "11,033",
"Other Compr. Net Income": "0",
"Other Expenses": "394,346",
"Other Liabilities": "0",
"Other Net Income": "222",
"Other Revenues": "581,939",
"Property, Plant and Equipment, Net": "60,754",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "59,696",
"Assets": "244,496",
"Expenses": "531,409",
"Revenues": "581,939",
"Stockholders Equity": "184,800",
"Net Income": "50,752",
"Comprehensive Net Income": "50,752",
"BaseVar": "708,881",
"ECR before LimitedLiability": "200%",
"Economic Capital Ratio": "235%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.3467191405294434,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000896264.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000896264.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000896264.svg"
},
{
"company_id": "0000811641",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000811641.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000811641.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000811641.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000811641_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000811641_main_keyfigs.svg",
"name": "Immucell CORP DE",
"rank": 10,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000811641.svg",
"report_text": "The relative strengths and weaknesses of Immucell CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immucell CORP DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 79% points.The greatest weakness of Immucell CORP DE is the variable Other Liabilities, reducing the Economic Capital Ratio by 21% points.
The company's Economic Capital Ratio, given in the ranking table, is 224%, being 71% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000811641_2012_Immucell_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "35.7",
"Liabilities": "30.0",
"Stockholders Equity": "78.7",
"ECR before LimitedLiability": "133",
"Liabilities, Non-Current": "11.4",
"Other Liabilities": "-21.1",
"Property, Plant and Equipment, Net": "7.45",
"Assets": "26.7",
"Assets, Non-Current": "-1.95",
"Other Assets": "6.85",
"Goodwill": "-4.32",
"Assets, Current": "15.6",
"General and Administrative Expense": "30.8",
"Expenses": "23.8",
"Revenues": "5.42",
"Net Income": "23.1",
"Research and Development": "-6.31",
"Other Revenues": "5.42",
"Comprehensive Net Income": "23.1",
"Other Net Income": "-6.15",
"Economic Capital Ratio": "70.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000811641_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,151",
"Assets, Non-Current": "19",
"General and Administrative Expense": "1,726",
"Goodwill": "0",
"Liabilities, Current": "635",
"Liabilities, Non-Current": "0",
"Other Assets": "1,306",
"Other Compr. Net Income": "0",
"Other Expenses": "2,010",
"Other Liabilities": "1,336",
"Other Net Income": "-64",
"Other Revenues": "5,111",
"Property, Plant and Equipment, Net": "2,515",
"Research and Development": "1,720"
},
"output_variables": {
"Liabilities": "1,971",
"Assets": "10,991",
"Expenses": "5,457",
"Revenues": "5,111",
"Stockholders Equity": "9,020",
"Net Income": "-410",
"Comprehensive Net Income": "-410",
"BaseVar": "11,797",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "224%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.241243326503436,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000811641.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000811641.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000811641.svg"
},
{
"company_id": "0000037785",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000037785.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000037785.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000037785_main_keyfigs.svg",
"name": "FMC CORP",
"rank": 11,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000037785.svg",
"report_text": "The relative strengths and weaknesses of FMC CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of FMC CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 47% points.The greatest weakness of FMC CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 221%, being 68% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000037785_2012_FMC_CORP.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "1.10",
"Liabilities": "-12.3",
"Stockholders Equity": "20.1",
"ECR before LimitedLiability": "9.42",
"Liabilities, Current": "-15.4",
"Other Liabilities": "1.64",
"Property, Plant and Equipment, Net": "6.68",
"Assets": "10.3",
"Other Assets": "4.39",
"Assets, Current": "-1.53",
"Goodwill": "0.287",
"General and Administrative Expense": "-28.3",
"Expenses": "12.9",
"Revenues": "-12.5",
"Comprehensive Net Income": "-0.188",
"Other Expenses": "39.8",
"Research and Development": "-0.0822",
"Other Revenues": "-12.5",
"Other Net Income": "-0.721",
"Other Compr. Net Income": "-0.157",
"Economic Capital Ratio": "8.70"
},
"2010": {
"Other Liabilities": "4.05",
"Liabilities": "23.4",
"Stockholders Equity": "10.1",
"ECR before LimitedLiability": "29.8",
"Liabilities, Current": "-21.9",
"Liabilities, Non-Current": "36.5",
"Other Expenses": "15.1",
"Expenses": "-3.63",
"Net Income": "14.6",
"General and Administrative Expense": "-24.5",
"Research and Development": "5.36",
"Other Revenues": "14.0",
"Revenues": "14.0",
"Goodwill": "-7.02",
"Property, Plant and Equipment, Net": "5.42",
"Assets, Current": "-4.49",
"Assets, Non-Current": "-2.70",
"Other Assets": "8.69",
"Other Net Income": "4.20",
"Comprehensive Net Income": "14.0",
"Economic Capital Ratio": "31.8"
},
"2011": {
"Liabilities, Current": "12.1",
"Liabilities": "38.3",
"Assets": "6.77",
"Stockholders Equity": "44.3",
"ECR before LimitedLiability": "130",
"Liabilities, Non-Current": "14.6",
"Other Liabilities": "15.3",
"Property, Plant and Equipment, Net": "7.10",
"Other Assets": "4.07",
"Assets, Current": "-3.03",
"General and Administrative Expense": "-12.1",
"Expenses": "20.0",
"Revenues": "34.4",
"Net Income": "46.8",
"Research and Development": "12.0",
"Other Expenses": "19.8",
"Other Revenues": "34.4",
"Comprehensive Net Income": "45.3",
"Other Net Income": "-8.00",
"Other Compr. Net Income": "-1.42",
"Economic Capital Ratio": "67.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000037785_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "1,487,700",
"Assets, Non-Current": "211,400",
"General and Administrative Expense": "2,265,900",
"Goodwill": "209,500",
"Liabilities, Current": "709,200",
"Liabilities, Non-Current": "0",
"Other Assets": "263,100",
"Other Compr. Net Income": "-13,400",
"Other Expenses": "213,000",
"Other Liabilities": "0",
"Other Net Income": "-15,700",
"Other Revenues": "2,826,200",
"Property, Plant and Equipment, Net": "964,500",
"Research and Development": "92,800"
},
"output_variables": {
"Liabilities": "709,200",
"Assets": "3,136,200",
"Expenses": "2,571,700",
"Revenues": "2,826,200",
"Stockholders Equity": "2,427,000",
"Net Income": "238,800",
"Comprehensive Net Income": "232,100",
"BaseVar": "4,636,200",
"ECR before LimitedLiability": "185%",
"Economic Capital Ratio": "225%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "1,646,200",
"Assets, Non-Current": "223,700",
"General and Administrative Expense": "2,476,800",
"Goodwill": "194,400",
"Liabilities, Current": "963,400",
"Liabilities, Non-Current": "0",
"Other Assets": "337,100",
"Other Compr. Net Income": "-44,900",
"Other Expenses": "323,400",
"Other Liabilities": "0",
"Other Net Income": "36,500",
"Other Revenues": "3,116,300",
"Property, Plant and Equipment, Net": "918,500",
"Research and Development": "100,500"
},
"output_variables": {
"Liabilities": "963,400",
"Assets": "3,319,900",
"Expenses": "2,900,700",
"Revenues": "3,116,300",
"Stockholders Equity": "2,356,500",
"Net Income": "252,100",
"Comprehensive Net Income": "229,650",
"BaseVar": "5,190,850",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "209%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,869,400",
"Assets, Non-Current": "198,900",
"General and Administrative Expense": "2,653,000",
"Goodwill": "413,200",
"Liabilities, Current": "919,900",
"Liabilities, Non-Current": "0",
"Other Assets": "275,200",
"Other Compr. Net Income": "-94,600",
"Other Expenses": "208,400",
"Other Liabilities": "0",
"Other Net Income": "-29,100",
"Other Revenues": "3,377,900",
"Property, Plant and Equipment, Net": "986,800",
"Research and Development": "105,200"
},
"output_variables": {
"Liabilities": "919,900",
"Assets": "3,743,500",
"Expenses": "2,966,600",
"Revenues": "3,377,900",
"Stockholders Equity": "2,823,600",
"Net Income": "382,200",
"Comprehensive Net Income": "334,900",
"BaseVar": "5,565,800",
"ECR before LimitedLiability": "180%",
"Economic Capital Ratio": "221%"
}
}
},
"top_rated": false,
"trend": -8.0,
"value": 2.2137058042163478,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000037785.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000037785.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000037785.svg"
},
{
"company_id": "0001054905",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001054905.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001054905.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001054905.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001054905_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001054905_main_keyfigs.svg",
"name": "Innospec INC",
"rank": 12,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001054905.svg",
"report_text": "The relative strengths and weaknesses of Innospec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Innospec INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 64% points.The greatest weakness of Innospec INC is the variable Other Expenses, reducing the Economic Capital Ratio by 78% points.
The company's Economic Capital Ratio, given in the ranking table, is 219%, being 66% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001054905_2012_Innospec_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.4",
"Liabilities": "60.0",
"Stockholders Equity": "21.0",
"ECR before LimitedLiability": "128",
"Liabilities, Non-Current": "18.6",
"Other Liabilities": "19.5",
"Property, Plant and Equipment, Net": "-4.79",
"Assets": "-7.47",
"Assets, Non-Current": "-3.61",
"Other Assets": "4.30",
"Goodwill": "6.41",
"Assets, Current": "-8.21",
"Other Revenues": "64.1",
"Revenues": "64.1",
"Net Income": "56.7",
"General and Administrative Expense": "55.2",
"Comprehensive Net Income": "57.8",
"Research and Development": "16.3",
"Other Net Income": "-8.06",
"Other Expenses": "-77.5",
"Economic Capital Ratio": "66.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001054905_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "320,300",
"Assets, Non-Current": "600",
"General and Administrative Expense": "155,900",
"Goodwill": "159,200",
"Liabilities, Current": "146,000",
"Liabilities, Non-Current": "0",
"Other Assets": "42,800",
"Other Compr. Net Income": "11,600",
"Other Expenses": "558,200",
"Other Liabilities": "0",
"Other Net Income": "6,900",
"Other Revenues": "774,400",
"Property, Plant and Equipment, Net": "45,900",
"Research and Development": "18,300"
},
"output_variables": {
"Liabilities": "146,000",
"Assets": "568,800",
"Expenses": "732,400",
"Revenues": "774,400",
"Stockholders Equity": "422,800",
"Net Income": "48,900",
"Comprehensive Net Income": "54,700",
"BaseVar": "1,120,050",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "219%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1943542275779144,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001054905.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001054905.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001054905.svg"
},
{
"company_id": "0001086303",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001086303.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001086303.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001086303.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001086303_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001086303_main_keyfigs.svg",
"name": "Hongchang International Co Ltd",
"rank": 13,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001086303.svg",
"report_text": "The relative strengths and weaknesses of Hongchang International Co Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hongchang International Co Ltd compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Hongchang International Co Ltd is the variable Other Revenues, reducing the Economic Capital Ratio by 35% points.
The company's Economic Capital Ratio, given in the ranking table, is 216%, being 62% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001086303_2012_Hongchang_International_Co_Ltd.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "15.5",
"Liabilities": "9.10",
"Stockholders Equity": "94.9",
"ECR before LimitedLiability": "124",
"Liabilities, Non-Current": "-16.9",
"Other Liabilities": "8.45",
"Property, Plant and Equipment, Net": "6.08",
"Assets": "57.0",
"Other Assets": "22.8",
"Goodwill": "7.32",
"Assets, Current": "3.22",
"General and Administrative Expense": "4.42",
"Expenses": "31.2",
"Revenues": "-35.4",
"Net Income": "9.31",
"Research and Development": "5.82",
"Other Expenses": "20.9",
"Other Revenues": "-35.4",
"Comprehensive Net Income": "9.28",
"Other Net Income": "12.0",
"Economic Capital Ratio": "62.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001086303_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,743",
"Assets, Non-Current": "0",
"General and Administrative Expense": "2,944",
"Goodwill": "1,946",
"Liabilities, Current": "972",
"Liabilities, Non-Current": "1,030",
"Other Assets": "3,190",
"Other Compr. Net Income": "0",
"Other Expenses": "-654",
"Other Liabilities": "0",
"Other Net Income": "1,526",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "1,815",
"Research and Development": "235"
},
"output_variables": {
"Liabilities": "2,002",
"Assets": "10,695",
"Expenses": "2,526",
"Revenues": "0",
"Stockholders Equity": "8,692",
"Net Income": "-1,000",
"Comprehensive Net Income": "-1,000",
"BaseVar": "8,375",
"ECR before LimitedLiability": "172%",
"Economic Capital Ratio": "216%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1573574385861143,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001086303.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001086303.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001086303.svg"
},
{
"company_id": "0000810509",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000810509.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000810509.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000810509.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000810509_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000810509_main_keyfigs.svg",
"name": "Navidea Biopharmaceuticals Inc",
"rank": 14,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000810509.svg",
"report_text": "The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Navidea Biopharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Navidea Biopharmaceuticals Inc is the variable Revenues, reducing the Economic Capital Ratio by 53% points.
The company's Economic Capital Ratio, given in the ranking table, is 213%, being 59% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000810509_2012_Navidea_Biopharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.9",
"Liabilities": "10.3",
"Stockholders Equity": "39.4",
"ECR before LimitedLiability": "121",
"Liabilities, Non-Current": "9.91",
"Other Liabilities": "-38.6",
"Property, Plant and Equipment, Net": "-5.14",
"Assets": "15.4",
"Assets, Non-Current": "-1.57",
"Goodwill": "-5.25",
"Assets, Current": "39.7",
"General and Administrative Expense": "21.2",
"Expenses": "31.2",
"Revenues": "-53.2",
"Net Income": "47.8",
"Research and Development": "-37.8",
"Other Expenses": "46.8",
"Other Revenues": "-53.2",
"Comprehensive Net Income": "47.7",
"Other Net Income": "69.0",
"Economic Capital Ratio": "59.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000810509_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,047",
"Assets, Non-Current": "599",
"General and Administrative Expense": "9,548",
"Goodwill": "85",
"Liabilities, Current": "3,348",
"Liabilities, Non-Current": "257",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-7,880",
"Other Liabilities": "6,456",
"Other Net Income": "22,435",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "463",
"Research and Development": "15,154"
},
"output_variables": {
"Liabilities": "10,062",
"Assets": "31,194",
"Expenses": "16,822",
"Revenues": "0",
"Stockholders Equity": "21,132",
"Net Income": "5,613",
"Comprehensive Net Income": "5,613",
"BaseVar": "40,257",
"ECR before LimitedLiability": "168%",
"Economic Capital Ratio": "213%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1290454266693963,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000810509.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000810509.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000810509.svg"
},
{
"company_id": "0001050007",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001050007.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001050007.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001050007_main_keyfigs.svg",
"name": "Nutraceutical International CORP",
"rank": 15,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001050007.svg",
"report_text": "The relative strengths and weaknesses of Nutraceutical International CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nutraceutical International CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 49% points.The greatest weakness of Nutraceutical International CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 208%, being 55% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001050007_2012_Nutraceutical_International_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "43.0",
"Liabilities": "36.2",
"Stockholders Equity": "25.2",
"ECR before LimitedLiability": "117",
"Liabilities, Non-Current": "14.8",
"Other Liabilities": "-27.0",
"General and Administrative Expense": "-26.3",
"Expenses": "11.9",
"Net Income": "49.4",
"Research and Development": "16.3",
"Other Expenses": "21.4",
"Other Revenues": "44.8",
"Revenues": "44.8",
"Property, Plant and Equipment, Net": "19.0",
"Assets, Non-Current": "-3.01",
"Other Assets": "2.65",
"Goodwill": "1.34",
"Assets, Current": "-13.4",
"Comprehensive Net Income": "49.4",
"Other Net Income": "-7.67",
"Economic Capital Ratio": "54.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001050007_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "62,069",
"Assets, Non-Current": "1,781",
"General and Administrative Expense": "161,107",
"Goodwill": "28,546",
"Liabilities, Current": "19,737",
"Liabilities, Non-Current": "253",
"Other Assets": "7,175",
"Other Compr. Net Income": "0",
"Other Expenses": "11,245",
"Other Liabilities": "32,000",
"Other Net Income": "0",
"Other Revenues": "188,070",
"Property, Plant and Equipment, Net": "72,094",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "51,990",
"Assets": "171,665",
"Expenses": "172,352",
"Revenues": "188,070",
"Stockholders Equity": "119,675",
"Net Income": "15,718",
"Comprehensive Net Income": "15,718",
"BaseVar": "292,038",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "208%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.083542392679,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001050007.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001050007.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001050007.svg"
},
{
"company_id": "0001374328",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001374328.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001374328.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001374328.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001374328_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001374328_main_keyfigs.svg",
"name": "Fitlife Brands INC",
"rank": 16,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001374328.svg",
"report_text": "The relative strengths and weaknesses of Fitlife Brands INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fitlife Brands INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 118% points.The greatest weakness of Fitlife Brands INC is the variable Other Expenses, reducing the Economic Capital Ratio by 133% points.
The company's Economic Capital Ratio, given in the ranking table, is 199%, being 46% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001374328_2012_Fitlife_Brands_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "53.4",
"Liabilities": "95.2",
"Stockholders Equity": "-40.7",
"ECR before LimitedLiability": "108",
"Liabilities, Non-Current": "25.7",
"Other Liabilities": "27.0",
"Property, Plant and Equipment, Net": "-14.6",
"Assets": "-33.5",
"Assets, Non-Current": "-6.95",
"Goodwill": "2.56",
"Assets, Current": "-23.4",
"General and Administrative Expense": "53.1",
"Expenses": "-37.8",
"Revenues": "118",
"Net Income": "86.8",
"Research and Development": "30.1",
"Other Expenses": "-133",
"Other Revenues": "118",
"Comprehensive Net Income": "86.7",
"Other Net Income": "-11.4",
"Economic Capital Ratio": "45.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001374328_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,296",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,675",
"Goodwill": "1,477",
"Liabilities, Current": "1,616",
"Liabilities, Non-Current": "0",
"Other Assets": "6.8",
"Other Compr. Net Income": "0",
"Other Expenses": "8,207",
"Other Liabilities": "0",
"Other Net Income": "118",
"Other Revenues": "12,092",
"Property, Plant and Equipment, Net": "43",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,616",
"Assets": "4,823",
"Expenses": "11,883",
"Revenues": "12,092",
"Stockholders Equity": "3,206",
"Net Income": "327",
"Comprehensive Net Income": "327",
"BaseVar": "15,266",
"ECR before LimitedLiability": "147%",
"Economic Capital Ratio": "199%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.9908188951410346,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001374328.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001374328.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001374328.svg"
},
{
"company_id": "0000722830",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000722830.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000722830.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000722830.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000722830_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000722830_main_keyfigs.svg",
"name": "Immunomedics INC",
"rank": 17,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000722830.svg",
"report_text": "The relative strengths and weaknesses of Immunomedics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immunomedics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points.The greatest weakness of Immunomedics INC is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.
The company's Economic Capital Ratio, given in the ranking table, is 183%, being 29% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000722830_2012_Immunomedics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "23.4",
"Liabilities": "46.6",
"Stockholders Equity": "78.3",
"ECR before LimitedLiability": "91.2",
"Liabilities, Non-Current": "12.7",
"Other Liabilities": "13.3",
"Property, Plant and Equipment, Net": "-1.99",
"Assets": "22.4",
"Assets, Non-Current": "-4.24",
"Other Assets": "1.72",
"Goodwill": "-9.02",
"Assets, Current": "52.4",
"General and Administrative Expense": "38.0",
"Expenses": "-11.1",
"Net Income": "-15.9",
"Other Net Income": "-5.26",
"Research and Development": "-71.3",
"Other Expenses": "24.3",
"Comprehensive Net Income": "-15.6",
"Other Revenues": "0.420",
"Economic Capital Ratio": "29.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000722830_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,258",
"Assets, Non-Current": "30",
"General and Administrative Expense": "7,944",
"Goodwill": "0",
"Liabilities, Current": "5,548",
"Liabilities, Non-Current": "0",
"Other Assets": "581",
"Other Compr. Net Income": "227",
"Other Expenses": "529",
"Other Liabilities": "0",
"Other Net Income": "480",
"Other Revenues": "18,117",
"Property, Plant and Equipment, Net": "3,456",
"Research and Development": "25,369"
},
"output_variables": {
"Liabilities": "5,548",
"Assets": "34,325",
"Expenses": "33,842",
"Revenues": "18,117",
"Stockholders Equity": "28,776",
"Net Income": "-15,244",
"Comprehensive Net Income": "-15,131",
"BaseVar": "46,270",
"ECR before LimitedLiability": "122%",
"Economic Capital Ratio": "183%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.8269614229071647,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000722830.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000722830.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000722830.svg"
},
{
"company_id": "0000874716",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000874716.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000874716.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000874716_main_keyfigs.svg",
"name": "Idexx Laboratories INC DE",
"rank": 18,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000874716.svg",
"report_text": "The relative strengths and weaknesses of Idexx Laboratories INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Idexx Laboratories INC DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Idexx Laboratories INC DE is the variable Other Assets, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 180%, being 27% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000874716_2012_Idexx_Laboratories_INC_DE.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "4.39",
"Liabilities": "21.9",
"Stockholders Equity": "-14.3",
"ECR before LimitedLiability": "23.6",
"Liabilities, Current": "-18.4",
"Liabilities, Non-Current": "32.6",
"Assets": "-11.3",
"Property, Plant and Equipment, Net": "0.217",
"Assets, Current": "-8.67",
"Assets, Non-Current": "28.2",
"Other Assets": "-18.8",
"Other Expenses": "21.1",
"Expenses": "-8.82",
"Revenues": "28.5",
"Net Income": "23.0",
"General and Administrative Expense": "-32.3",
"Research and Development": "1.98",
"Other Revenues": "28.5",
"Other Net Income": "3.49",
"Comprehensive Net Income": "23.1",
"Economic Capital Ratio": "25.6"
},
"2011": {
"Liabilities, Current": "-10.1",
"Liabilities": "9.33",
"Stockholders Equity": "-4.45",
"ECR before LimitedLiability": "88.9",
"Liabilities, Non-Current": "4.54",
"Other Liabilities": "14.3",
"Assets": "-5.93",
"Assets, Non-Current": "45.2",
"Other Assets": "-23.7",
"Goodwill": "5.99",
"Assets, Current": "-11.7",
"General and Administrative Expense": "-12.4",
"Expenses": "17.7",
"Revenues": "45.9",
"Net Income": "58.1",
"Research and Development": "9.32",
"Other Expenses": "21.3",
"Other Revenues": "45.9",
"Comprehensive Net Income": "58.1",
"Other Net Income": "-7.26",
"Economic Capital Ratio": "26.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000874716_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "460,591",
"Assets, Non-Current": "436,553",
"General and Administrative Expense": "830,914",
"Goodwill": "204,864",
"Liabilities, Current": "285,112",
"Liabilities, Non-Current": "37,751",
"Other Assets": "-406,589",
"Other Compr. Net Income": "0",
"Other Expenses": "63,224",
"Other Liabilities": "0",
"Other Net Income": "663",
"Other Revenues": "1,103,392",
"Property, Plant and Equipment, Net": "201,725",
"Research and Development": "68,597"
},
"output_variables": {
"Liabilities": "322,863",
"Assets": "897,144",
"Expenses": "962,735",
"Revenues": "1,103,392",
"Stockholders Equity": "574,281",
"Net Income": "141,320",
"Comprehensive Net Income": "141,320",
"BaseVar": "1,643,398",
"ECR before LimitedLiability": "152%",
"Economic Capital Ratio": "203%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "524,227",
"Assets, Non-Current": "506,587",
"General and Administrative Expense": "906,422",
"Goodwill": "241,819",
"Liabilities, Current": "436,879",
"Liabilities, Non-Current": "54,342",
"Other Assets": "-458,596",
"Other Compr. Net Income": "0",
"Other Expenses": "76,215",
"Other Liabilities": "0",
"Other Net Income": "1,744",
"Other Revenues": "1,218,689",
"Property, Plant and Equipment, Net": "216,777",
"Research and Development": "76,042"
},
"output_variables": {
"Liabilities": "491,221",
"Assets": "1,030,814",
"Expenses": "1,058,679",
"Revenues": "1,218,689",
"Stockholders Equity": "539,593",
"Net Income": "161,754",
"Comprehensive Net Income": "161,754",
"BaseVar": "1,900,574",
"ECR before LimitedLiability": "118%",
"Economic Capital Ratio": "180%"
}
}
},
"top_rated": false,
"trend": -14.0,
"value": 1.8037169631872847,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000874716.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000874716.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000874716.svg"
},
{
"company_id": "0000722104",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000722104.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000722104.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000722104_main_keyfigs.svg",
"name": "Savient Pharmaceuticals INC",
"rank": 19,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000722104.svg",
"report_text": "The relative strengths and weaknesses of Savient Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Savient Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points.The greatest weakness of Savient Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 36% points.
The company's Economic Capital Ratio, given in the ranking table, is 176%, being 22% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000722104_2012_Savient_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Liabilities": "13.5",
"Stockholders Equity": "21.7",
"ECR before LimitedLiability": "-77.3",
"Liabilities, Current": "-19.7",
"Liabilities, Non-Current": "17.4",
"Goodwill": "-23.3",
"Assets": "20.8",
"Property, Plant and Equipment, Net": "-21.3",
"Assets, Current": "52.4",
"Assets, Non-Current": "-12.2",
"Other Assets": "16.9",
"Other Expenses": "17.2",
"Expenses": "-23.4",
"Revenues": "-68.8",
"Net Income": "-108",
"General and Administrative Expense": "7.69",
"Research and Development": "-48.4",
"Other Revenues": "-68.8",
"Other Net Income": "-28.3",
"Comprehensive Net Income": "-108",
"Economic Capital Ratio": "-75.3"
},
"2011": {
"Liabilities, Current": "6.01",
"Liabilities": "22.8",
"Stockholders Equity": "92.4",
"ECR before LimitedLiability": "84.3",
"Liabilities, Non-Current": "8.51",
"Other Liabilities": "8.95",
"Property, Plant and Equipment, Net": "-6.96",
"Assets": "91.2",
"Assets, Non-Current": "-1.98",
"Other Assets": "2.18",
"Goodwill": "-6.74",
"Assets, Current": "102",
"Other Revenues": "-34.5",
"Revenues": "-34.5",
"Net Income": "-36.3",
"General and Administrative Expense": "-11.8",
"Comprehensive Net Income": "-36.3",
"Research and Development": "-4.81",
"Other Net Income": "-3.27",
"Other Expenses": "18.8",
"Economic Capital Ratio": "22.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000722104_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "71,325",
"Assets, Non-Current": "1,284",
"General and Administrative Expense": "24,981",
"Goodwill": "0",
"Liabilities, Current": "18,052",
"Liabilities, Non-Current": "0",
"Other Assets": "4,200",
"Other Compr. Net Income": "0",
"Other Expenses": "2,664",
"Other Liabilities": "0",
"Other Net Income": "-17,134",
"Other Revenues": "4,028",
"Property, Plant and Equipment, Net": "809",
"Research and Development": "32,358"
},
"output_variables": {
"Liabilities": "18,052",
"Assets": "77,618",
"Expenses": "60,003",
"Revenues": "4,028",
"Stockholders Equity": "59,566",
"Net Income": "-73,109",
"Comprehensive Net Income": "-73,109",
"BaseVar": "88,418",
"ECR before LimitedLiability": "18%",
"Economic Capital Ratio": "102%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "189,635",
"Assets, Non-Current": "2,580",
"General and Administrative Expense": "90,898",
"Goodwill": "0",
"Liabilities, Current": "30,065",
"Liabilities, Non-Current": "0",
"Other Assets": "4,068",
"Other Compr. Net Income": "14",
"Other Expenses": "-1,738",
"Other Liabilities": "0",
"Other Net Income": "2,358",
"Other Revenues": "9,565",
"Property, Plant and Equipment, Net": "833",
"Research and Development": "24,790"
},
"output_variables": {
"Liabilities": "30,065",
"Assets": "197,116",
"Expenses": "113,950",
"Revenues": "9,565",
"Stockholders Equity": "167,051",
"Net Income": "-102,027",
"Comprehensive Net Income": "-102,020",
"BaseVar": "176,534",
"ECR before LimitedLiability": "112%",
"Economic Capital Ratio": "176%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 1.7581158528421557,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000722104.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000722104.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000722104.svg"
},
{
"company_id": "0001063665",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001063665.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001063665.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001063665_main_keyfigs.svg",
"name": "Corgenix Medical CORP CO",
"rank": 20,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001063665.svg",
"report_text": "The relative strengths and weaknesses of Corgenix Medical CORP CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Corgenix Medical CORP CO compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Corgenix Medical CORP CO is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 175%, being 22% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001063665_2012_Corgenix_Medical_CORP_CO.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "11.9",
"Liabilities": "25.3",
"Stockholders Equity": "5.09",
"ECR before LimitedLiability": "83.5",
"Liabilities, Non-Current": "12.8",
"Other Liabilities": "1.27",
"Property, Plant and Equipment, Net": "-1.34",
"Assets": "-7.69",
"Assets, Non-Current": "-4.55",
"Goodwill": "-8.20",
"Assets, Current": "6.79",
"General and Administrative Expense": "-29.8",
"Expenses": "3.33",
"Revenues": "44.2",
"Net Income": "38.5",
"Research and Development": "15.0",
"Other Expenses": "19.9",
"Other Revenues": "44.2",
"Comprehensive Net Income": "38.3",
"Other Net Income": "-8.03",
"Economic Capital Ratio": "21.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001063665_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,466",
"Assets, Non-Current": "82",
"General and Administrative Expense": "7,397",
"Goodwill": "317",
"Liabilities, Current": "2,149",
"Liabilities, Non-Current": "66",
"Other Assets": "12",
"Other Compr. Net Income": "-17",
"Other Expenses": "744",
"Other Liabilities": "534",
"Other Net Income": "0.85",
"Other Revenues": "7,942",
"Property, Plant and Equipment, Net": "1,076",
"Research and Development": "194"
},
"output_variables": {
"Liabilities": "2,749",
"Assets": "6,953",
"Expenses": "8,335",
"Revenues": "7,942",
"Stockholders Equity": "4,204",
"Net Income": "-393",
"Comprehensive Net Income": "-402",
"BaseVar": "12,998",
"ECR before LimitedLiability": "110%",
"Economic Capital Ratio": "175%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.7499281232218906,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001063665.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001063665.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001063665.svg"
},
{
"company_id": "0001141240",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001141240.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001141240.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001141240.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001141240_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001141240_main_keyfigs.svg",
"name": "Liquidmetal Technologies INC",
"rank": 21,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001141240.svg",
"report_text": "The relative strengths and weaknesses of Liquidmetal Technologies INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Liquidmetal Technologies INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 155% points.The greatest weakness of Liquidmetal Technologies INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 217% points.
The company's Economic Capital Ratio, given in the ranking table, is 168%, being 14% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001141240_2012_Liquidmetal_Technologies_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-40.4",
"Liabilities": "-11.9",
"Stockholders Equity": "-217",
"ECR before LimitedLiability": "76.3",
"Liabilities, Non-Current": "-1.08",
"Other Liabilities": "24.7",
"Property, Plant and Equipment, Net": "-17.8",
"Assets": "-57.7",
"Assets, Non-Current": "-8.47",
"Goodwill": "-3.55",
"Assets, Current": "-48.1",
"General and Administrative Expense": "21.1",
"Expenses": "36.6",
"Revenues": "-96.1",
"Net Income": "132",
"Research and Development": "4.07",
"Other Expenses": "9.81",
"Other Revenues": "-96.1",
"Comprehensive Net Income": "132",
"Other Net Income": "155",
"Economic Capital Ratio": "14.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001141240_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "811",
"Assets, Non-Current": "52",
"General and Administrative Expense": "4,616",
"Goodwill": "968",
"Liabilities, Current": "3,610",
"Liabilities, Non-Current": "609",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,803",
"Other Liabilities": "0",
"Other Net Income": "12,722",
"Other Revenues": "972",
"Property, Plant and Equipment, Net": "162",
"Research and Development": "1,120"
},
"output_variables": {
"Liabilities": "4,219",
"Assets": "1,993",
"Expenses": "7,539",
"Revenues": "972",
"Stockholders Equity": "-2,226",
"Net Income": "6,155",
"Comprehensive Net Income": "6,155",
"BaseVar": "13,722",
"ECR before LimitedLiability": "100%",
"Economic Capital Ratio": "168%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.6775120551727398,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001141240.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001141240.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001141240.svg"
},
{
"company_id": "0000074303",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000074303.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000074303.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000074303_main_keyfigs.svg",
"name": "OLIN Corp",
"rank": 22,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000074303.svg",
"report_text": "The relative strengths and weaknesses of OLIN Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of OLIN Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points.The greatest weakness of OLIN Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 61% points.
The company's Economic Capital Ratio, given in the ranking table, is 154%, being 0.97% points above the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000074303_2012_OLIN_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Liabilities": "-32.8",
"Stockholders Equity": "-28.9",
"ECR before LimitedLiability": "-30.5",
"Liabilities, Current": "1.73",
"Liabilities, Non-Current": "-36.2",
"Goodwill": "-4.33",
"Assets": "-4.43",
"Property, Plant and Equipment, Net": "15.0",
"Assets, Current": "-12.7",
"Assets, Non-Current": "-7.23",
"Other Assets": "9.43",
"Other Expenses": "21.0",
"Expenses": "8.06",
"Revenues": "-3.03",
"Net Income": "9.56",
"General and Administrative Expense": "-19.2",
"Research and Development": "8.02",
"Other Revenues": "-3.03",
"Other Net Income": "4.53",
"Comprehensive Net Income": "9.63",
"Economic Capital Ratio": "-28.5"
},
"2011": {
"Liabilities, Current": "25.7",
"Liabilities": "-22.1",
"Stockholders Equity": "-11.3",
"ECR before LimitedLiability": "63.0",
"Liabilities, Non-Current": "-61.5",
"Other Liabilities": "5.23",
"Property, Plant and Equipment, Net": "22.8",
"Assets": "3.43",
"Assets, Non-Current": "-2.36",
"Other Assets": "2.89",
"Goodwill": "11.7",
"Assets, Current": "-21.4",
"General and Administrative Expense": "-4.85",
"Expenses": "28.8",
"Revenues": "16.3",
"Net Income": "47.9",
"Research and Development": "14.7",
"Other Expenses": "18.4",
"Other Revenues": "16.3",
"Comprehensive Net Income": "47.8",
"Economic Capital Ratio": "0.966"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000074303_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "882,800",
"Assets, Non-Current": "72,300",
"General and Administrative Expense": "1,484,300",
"Goodwill": "300,300",
"Liabilities, Current": "391,000",
"Liabilities, Non-Current": "803,900",
"Other Assets": "118,300",
"Other Compr. Net Income": "0",
"Other Expenses": "71,700",
"Other Liabilities": "23,500",
"Other Net Income": "34,900",
"Other Revenues": "1,585,900",
"Property, Plant and Equipment, Net": "675,000",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,218,400",
"Assets": "2,048,700",
"Expenses": "1,556,000",
"Revenues": "1,585,900",
"Stockholders Equity": "830,300",
"Net Income": "64,800",
"Comprehensive Net Income": "64,800",
"BaseVar": "3,221,950",
"ECR before LimitedLiability": "74%",
"Economic Capital Ratio": "149%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "780,300",
"Assets, Non-Current": "85,600",
"General and Administrative Expense": "1,735,300",
"Goodwill": "627,400",
"Liabilities, Current": "399,100",
"Liabilities, Non-Current": "965,100",
"Other Assets": "70,900",
"Other Compr. Net Income": "0",
"Other Expenses": "178,800",
"Other Liabilities": "99,600",
"Other Net Income": "185,900",
"Other Revenues": "1,969,900",
"Property, Plant and Equipment, Net": "885,400",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,463,800",
"Assets": "2,449,600",
"Expenses": "1,914,100",
"Revenues": "1,969,900",
"Stockholders Equity": "985,800",
"Net Income": "241,700",
"Comprehensive Net Income": "241,700",
"BaseVar": "3,991,650",
"ECR before LimitedLiability": "81%",
"Economic Capital Ratio": "154%"
}
}
},
"top_rated": false,
"trend": -16.0,
"value": 1.5442233371592051,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000074303.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000074303.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000074303.svg"
},
{
"company_id": "0000744218",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000744218.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000744218.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000744218.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000744218_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000744218_main_keyfigs.svg",
"name": "Celldex Therapeutics Inc",
"rank": 23,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000744218.svg",
"report_text": "The relative strengths and weaknesses of Celldex Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Celldex Therapeutics Inc compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 67% points.The greatest weakness of Celldex Therapeutics Inc is the variable Revenues, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 152%, being 1.9% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000744218_2012_Celldex_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "9.86",
"Liabilities": "-3.63",
"Stockholders Equity": "67.0",
"ECR before LimitedLiability": "60.1",
"Liabilities, Non-Current": "-3.93",
"Other Liabilities": "-9.89",
"Property, Plant and Equipment, Net": "0.343",
"Assets": "67.5",
"Assets, Non-Current": "-3.70",
"Goodwill": "40.9",
"Assets, Current": "26.4",
"General and Administrative Expense": "37.3",
"Expenses": "10.4",
"Revenues": "-30.9",
"Net Income": "-25.8",
"Research and Development": "-26.0",
"Other Expenses": "3.29",
"Other Revenues": "-30.9",
"Comprehensive Net Income": "-25.9",
"Other Net Income": "-4.47",
"Economic Capital Ratio": "-1.92"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000744218_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "54,684",
"Assets, Non-Current": "329",
"General and Administrative Expense": "9,243",
"Goodwill": "33,888",
"Liabilities, Current": "14,298",
"Liabilities, Non-Current": "5,966",
"Other Assets": "0",
"Other Compr. Net Income": "-99",
"Other Expenses": "12,778",
"Other Liabilities": "9,008",
"Other Net Income": "396",
"Other Revenues": "9,265",
"Property, Plant and Equipment, Net": "9,093",
"Research and Development": "32,439"
},
"output_variables": {
"Liabilities": "29,272",
"Assets": "97,994",
"Expenses": "54,460",
"Revenues": "9,265",
"Stockholders Equity": "68,722",
"Net Income": "-44,799",
"Comprehensive Net Income": "-44,848",
"BaseVar": "95,743",
"ECR before LimitedLiability": "77%",
"Economic Capital Ratio": "152%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.5153678010400191,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000744218.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000744218.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000744218.svg"
},
{
"company_id": "0001315695",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001315695.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001315695.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001315695_main_keyfigs.svg",
"name": "Rockwood Holdings Inc",
"rank": 24,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001315695.svg",
"report_text": "The relative strengths and weaknesses of Rockwood Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rockwood Holdings Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 47% points.The greatest weakness of Rockwood Holdings Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 47% points.
The company's Economic Capital Ratio, given in the ranking table, is 148%, being 5.2% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001315695_2012_Rockwood_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "-13.2",
"Liabilities": "-55.1",
"Stockholders Equity": "-39.2",
"ECR before LimitedLiability": "-47.5",
"Liabilities, Current": "-6.11",
"Liabilities, Non-Current": "-32.9",
"Goodwill": "14.7",
"Assets": "-0.454",
"Property, Plant and Equipment, Net": "18.1",
"Assets, Current": "-19.3",
"Assets, Non-Current": "-10.1",
"Other Assets": "4.39",
"Other Expenses": "23.9",
"Expenses": "21.3",
"Revenues": "-9.01",
"Net Income": "11.4",
"General and Administrative Expense": "-9.75",
"Research and Development": "7.73",
"Other Revenues": "-9.01",
"Comprehensive Net Income": "11.5",
"Economic Capital Ratio": "-45.5"
},
"2011": {
"Liabilities, Current": "20.4",
"Liabilities": "-31.3",
"Stockholders Equity": "-13.7",
"ECR before LimitedLiability": "56.8",
"Liabilities, Non-Current": "-47.3",
"Other Liabilities": "-7.61",
"Property, Plant and Equipment, Net": "23.4",
"Assets": "7.15",
"Assets, Non-Current": "-4.54",
"Goodwill": "17.6",
"Assets, Current": "-19.9",
"General and Administrative Expense": "-3.78",
"Expenses": "33.1",
"Revenues": "18.2",
"Net Income": "46.6",
"Research and Development": "14.2",
"Other Expenses": "21.8",
"Other Revenues": "18.2",
"Comprehensive Net Income": "46.5",
"Other Net Income": "-6.17",
"Economic Capital Ratio": "-5.19"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001315695_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,618,600",
"Assets, Non-Current": "38,500",
"General and Administrative Expense": "2,817,400",
"Goodwill": "1,464,700",
"Liabilities, Current": "1,095,800",
"Liabilities, Non-Current": "1,799,600",
"Other Assets": "35,600",
"Other Compr. Net Income": "0",
"Other Expenses": "-8,100",
"Other Liabilities": "477,500",
"Other Net Income": "-133,800",
"Other Revenues": "3,191,600",
"Property, Plant and Equipment, Net": "1,566,900",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,372,900",
"Assets": "4,724,300",
"Expenses": "2,809,300",
"Revenues": "3,191,600",
"Stockholders Equity": "1,351,400",
"Net Income": "248,500",
"Comprehensive Net Income": "248,500",
"BaseVar": "7,115,950",
"ECR before LimitedLiability": "52%",
"Economic Capital Ratio": "132%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,535,200",
"Assets, Non-Current": "41,000",
"General and Administrative Expense": "3,085,900",
"Goodwill": "1,359,300",
"Liabilities, Current": "840,200",
"Liabilities, Non-Current": "1,537,800",
"Other Assets": "33,600",
"Other Compr. Net Income": "0",
"Other Expenses": "140,500",
"Other Liabilities": "537,200",
"Other Net Income": "9,000",
"Other Revenues": "3,669,300",
"Property, Plant and Equipment, Net": "1,618,500",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "2,915,200",
"Assets": "4,587,600",
"Expenses": "3,226,400",
"Revenues": "3,669,300",
"Stockholders Equity": "1,672,400",
"Net Income": "451,900",
"Comprehensive Net Income": "451,900",
"BaseVar": "7,203,750",
"ECR before LimitedLiability": "73%",
"Economic Capital Ratio": "148%"
}
}
},
"top_rated": false,
"trend": -17.0,
"value": 1.4826921867543488,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001315695.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001315695.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001315695.svg"
},
{
"company_id": "0001407038",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001407038.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001407038.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001407038_main_keyfigs.svg",
"name": "BG Medicine Inc",
"rank": 25,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001407038.svg",
"report_text": "The relative strengths and weaknesses of BG Medicine Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of BG Medicine Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points.The greatest weakness of BG Medicine Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 52% points.
The company's Economic Capital Ratio, given in the ranking table, is 146%, being 7.2% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001407038_2012_BG_Medicine_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.159",
"Liabilities": "18.6",
"Stockholders Equity": "65.0",
"ECR before LimitedLiability": "54.8",
"Liabilities, Non-Current": "9.17",
"Other Liabilities": "9.52",
"Property, Plant and Equipment, Net": "-9.53",
"Assets": "63.9",
"Assets, Non-Current": "-4.73",
"Other Assets": "0.406",
"Goodwill": "-8.03",
"Assets, Current": "87.3",
"Expenses": "-9.56",
"Revenues": "-38.4",
"Net Income": "-51.8",
"Research and Development": "-25.5",
"Other Expenses": "17.9",
"Other Revenues": "-38.4",
"Comprehensive Net Income": "-51.9",
"Other Net Income": "-5.60",
"Economic Capital Ratio": "-7.19"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001407038_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,316",
"Assets, Non-Current": "0",
"General and Administrative Expense": "10,502",
"Goodwill": "456",
"Liabilities, Current": "5,203",
"Liabilities, Non-Current": "0",
"Other Assets": "37",
"Other Compr. Net Income": "0",
"Other Expenses": "708",
"Other Liabilities": "15",
"Other Net Income": "-8.0",
"Other Revenues": "1,634",
"Property, Plant and Equipment, Net": "301",
"Research and Development": "7,998"
},
"output_variables": {
"Liabilities": "5,218",
"Assets": "26,110",
"Expenses": "19,208",
"Revenues": "1,634",
"Stockholders Equity": "20,892",
"Net Income": "-17,582",
"Comprehensive Net Income": "-17,582",
"BaseVar": "26,089",
"ECR before LimitedLiability": "70%",
"Economic Capital Ratio": "146%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4626394031206007,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001407038.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001407038.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001407038.svg"
},
{
"company_id": "0000949858",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000949858.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000949858.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000949858.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000949858_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000949858_main_keyfigs.svg",
"name": "Achieve LIFE Sciences INC",
"rank": 26,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000949858.svg",
"report_text": "The relative strengths and weaknesses of Achieve LIFE Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Achieve LIFE Sciences INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 59% points.The greatest weakness of Achieve LIFE Sciences INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 132%, being 21% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000949858_2012_Achieve_LIFE_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-43.8",
"Liabilities": "-43.7",
"Stockholders Equity": "19.4",
"ECR before LimitedLiability": "40.7",
"Liabilities, Non-Current": "7.76",
"Other Liabilities": "-7.86",
"Property, Plant and Equipment, Net": "-10.3",
"Assets": "48.0",
"Assets, Non-Current": "-3.79",
"Goodwill": "-9.74",
"Assets, Current": "59.2",
"General and Administrative Expense": "39.1",
"Expenses": "34.1",
"Revenues": "-40.2",
"Net Income": "2.87",
"Research and Development": "-21.6",
"Other Expenses": "19.2",
"Other Revenues": "-40.2",
"Comprehensive Net Income": "2.83",
"Other Net Income": "15.9",
"Economic Capital Ratio": "-21.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000949858_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "67,326",
"Assets, Non-Current": "509",
"General and Administrative Expense": "6,230",
"Goodwill": "0",
"Liabilities, Current": "30,786",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "6,339",
"Other Net Income": "13,110",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "180",
"Research and Development": "21,553"
},
"output_variables": {
"Liabilities": "37,125",
"Assets": "68,015",
"Expenses": "27,783",
"Revenues": "0",
"Stockholders Equity": "30,890",
"Net Income": "-14,673",
"Comprehensive Net Income": "-14,673",
"BaseVar": "73,016",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "132%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3217336226355427,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000949858.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000949858.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000949858.svg"
},
{
"company_id": "0001145460",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001145460.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001145460.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001145460_main_keyfigs.svg",
"name": "Alere INC",
"rank": 27,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001145460.svg",
"report_text": "The relative strengths and weaknesses of Alere INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alere INC compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 53% points.The greatest weakness of Alere INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 102% points.
The company's Economic Capital Ratio, given in the ranking table, is 127%, being 26% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001145460_2012_Alere_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "2.41",
"Liabilities": "-50.0",
"Stockholders Equity": "-12.7",
"ECR before LimitedLiability": "-49.1",
"Liabilities, Current": "5.50",
"Liabilities, Non-Current": "-59.8",
"Goodwill": "54.9",
"Assets": "25.5",
"Property, Plant and Equipment, Net": "-9.25",
"Assets, Current": "-24.8",
"Assets, Non-Current": "-7.27",
"Other Assets": "4.17",
"Expenses": "15.9",
"Revenues": "-27.8",
"Net Income": "-10.9",
"General and Administrative Expense": "9.38",
"Research and Development": "4.56",
"Other Revenues": "-27.8",
"Other Net Income": "3.19",
"Comprehensive Net Income": "-10.8",
"Economic Capital Ratio": "-47.1"
},
"2011": {
"Liabilities, Current": "23.6",
"Liabilities": "-54.7",
"Stockholders Equity": "-5.04",
"ECR before LimitedLiability": "35.7",
"Liabilities, Non-Current": "-102",
"Other Liabilities": "8.69",
"Property, Plant and Equipment, Net": "-4.30",
"Assets": "41.2",
"Assets, Non-Current": "-2.13",
"Goodwill": "53.1",
"Assets, Current": "-24.9",
"General and Administrative Expense": "18.5",
"Expenses": "41.6",
"Revenues": "-11.6",
"Net Income": "21.6",
"Research and Development": "9.58",
"Other Expenses": "11.1",
"Other Revenues": "-11.6",
"Comprehensive Net Income": "21.6",
"Other Net Income": "-5.35",
"Economic Capital Ratio": "-26.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001145460_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,194,257",
"Assets, Non-Current": "153,361",
"General and Administrative Expense": "1,966,801",
"Goodwill": "4,538,881",
"Liabilities, Current": "782,858",
"Liabilities, Non-Current": "2,969,790",
"Other Assets": "53,365",
"Other Compr. Net Income": "0",
"Other Expenses": "1,115,861",
"Other Liabilities": "0",
"Other Net Income": "44,701",
"Other Revenues": "2,155,347",
"Property, Plant and Equipment, Net": "390,510",
"Research and Development": "133,278"
},
"output_variables": {
"Liabilities": "3,752,648",
"Assets": "6,330,374",
"Expenses": "3,215,940",
"Revenues": "2,155,347",
"Stockholders Equity": "2,577,726",
"Net Income": "-1,015,892",
"Comprehensive Net Income": "-1,015,892",
"BaseVar": "7,749,505",
"ECR before LimitedLiability": "50%",
"Economic Capital Ratio": "130%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,293,727",
"Assets, Non-Current": "185,178",
"General and Administrative Expense": "2,105,605",
"Goodwill": "4,607,196",
"Liabilities, Current": "624,452",
"Liabilities, Non-Current": "3,814,178",
"Other Assets": "95,395",
"Other Compr. Net Income": "0",
"Other Expenses": "611,797",
"Other Liabilities": "0",
"Other Net Income": "1,883",
"Other Revenues": "2,386,527",
"Property, Plant and Equipment, Net": "491,205",
"Research and Development": "150,165"
},
"output_variables": {
"Liabilities": "4,438,630",
"Assets": "6,672,701",
"Expenses": "2,867,567",
"Revenues": "2,386,527",
"Stockholders Equity": "2,234,071",
"Net Income": "-479,157",
"Comprehensive Net Income": "-479,157",
"BaseVar": "8,183,654",
"ECR before LimitedLiability": "46%",
"Economic Capital Ratio": "127%"
}
}
},
"top_rated": false,
"trend": -19.0,
"value": 1.2713022696923149,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001145460.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001145460.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001145460.svg"
},
{
"company_id": "0001307954",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001307954.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001307954.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001307954.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001307954_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001307954_main_keyfigs.svg",
"name": "Huntsman CORP",
"rank": 28,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001307954.svg",
"report_text": "The relative strengths and weaknesses of Huntsman CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Huntsman CORP compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Huntsman CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 77% points.
The company's Economic Capital Ratio, given in the ranking table, is 115%, being 38% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001307954_2012_Huntsman_CORP.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "-2.03",
"Liabilities": "-45.4",
"Stockholders Equity": "-67.7",
"ECR before LimitedLiability": "-63.6",
"Liabilities, Current": "2.22",
"Liabilities, Non-Current": "-45.6",
"Goodwill": "-21.9",
"Assets": "-28.8",
"Property, Plant and Equipment, Net": "24.7",
"Assets, Current": "-25.7",
"Assets, Non-Current": "-6.92",
"Other Assets": "7.77",
"Other Revenues": "5.95",
"Revenues": "5.95",
"Net Income": "8.75",
"Comprehensive Net Income": "8.76",
"Research and Development": "8.63",
"Other Net Income": "2.35",
"Other Expenses": "-53.9",
"General and Administrative Expense": "32.3",
"Economic Capital Ratio": "-61.6"
},
"2011": {
"Liabilities, Current": "30.9",
"Liabilities": "-25.6",
"Stockholders Equity": "-54.5",
"ECR before LimitedLiability": "24.0",
"Liabilities, Non-Current": "-77.2",
"Other Liabilities": "9.20",
"Property, Plant and Equipment, Net": "30.9",
"Assets": "-28.2",
"Other Assets": "3.25",
"Goodwill": "-16.8",
"Assets, Current": "-33.8",
"General and Administrative Expense": "36.1",
"Expenses": "18.4",
"Revenues": "31.4",
"Net Income": "32.1",
"Research and Development": "19.3",
"Other Expenses": "-66.2",
"Other Revenues": "31.4",
"Comprehensive Net Income": "31.9",
"Other Net Income": "-9.30",
"Economic Capital Ratio": "-38.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001307954_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "4,008,000",
"Assets, Non-Current": "729,000",
"General and Administrative Expense": "861,000",
"Goodwill": "199,000",
"Liabilities, Current": "2,053,000",
"Liabilities, Non-Current": "4,493,000",
"Other Assets": "173,000",
"Other Compr. Net Income": "-15,000",
"Other Expenses": "8,086,000",
"Other Liabilities": "318,000",
"Other Net Income": "-122,000",
"Other Revenues": "9,252,000",
"Property, Plant and Equipment, Net": "3,605,000",
"Research and Development": "151,000"
},
"output_variables": {
"Liabilities": "6,864,000",
"Assets": "8,714,000",
"Expenses": "9,098,000",
"Revenues": "9,252,000",
"Stockholders Equity": "1,850,000",
"Net Income": "32,000",
"Comprehensive Net Income": "24,500",
"BaseVar": "17,032,500",
"ECR before LimitedLiability": "33%",
"Economic Capital Ratio": "115%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "3,946,000",
"Assets, Non-Current": "684,000",
"General and Administrative Expense": "921,000",
"Goodwill": "205,000",
"Liabilities, Current": "1,826,000",
"Liabilities, Non-Current": "4,742,000",
"Other Assets": "200,000",
"Other Compr. Net Income": "-269,000",
"Other Expenses": "9,886,000",
"Other Liabilities": "313,000",
"Other Net Income": "4,000",
"Other Revenues": "11,223,000",
"Property, Plant and Equipment, Net": "3,622,000",
"Research and Development": "166,000"
},
"output_variables": {
"Liabilities": "6,881,000",
"Assets": "8,657,000",
"Expenses": "10,973,000",
"Revenues": "11,223,000",
"Stockholders Equity": "1,776,000",
"Net Income": "254,000",
"Comprehensive Net Income": "119,500",
"BaseVar": "19,003,500",
"ECR before LimitedLiability": "33%",
"Economic Capital Ratio": "115%"
}
}
},
"top_rated": false,
"trend": -19.0,
"value": 1.1547884436168878,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001307954.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001307954.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001307954.svg"
},
{
"company_id": "0001056358",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001056358.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001056358.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001056358_main_keyfigs.svg",
"name": "Mannatech INC",
"rank": 29,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001056358.svg",
"report_text": "The relative strengths and weaknesses of Mannatech INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mannatech INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Mannatech INC is the variable Other Expenses, reducing the Economic Capital Ratio by 141% points.
The company's Economic Capital Ratio, given in the ranking table, is 104%, being 50% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001056358_2012_Mannatech_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "-3.85",
"Liabilities": "-9.05",
"Stockholders Equity": "-140",
"ECR before LimitedLiability": "-70.0",
"Other Liabilities": "-5.76",
"Property, Plant and Equipment, Net": "-17.3",
"Assets": "-58.1",
"Other Assets": "9.04",
"Assets, Current": "-42.8",
"Assets, Non-Current": "-13.3",
"Goodwill": "-14.0",
"General and Administrative Expense": "3.92",
"Expenses": "-62.6",
"Revenues": "34.1",
"Net Income": "-34.3",
"Other Expenses": "-72.3",
"Research and Development": "7.47",
"Other Revenues": "34.1",
"Comprehensive Net Income": "-34.2",
"Other Net Income": "1.13",
"Economic Capital Ratio": "-70.7"
},
"2010": {
"Liabilities": "65.1",
"Stockholders Equity": "-124",
"ECR before LimitedLiability": "-29.4",
"Liabilities, Current": "11.6",
"Liabilities, Non-Current": "59.2",
"Goodwill": "-32.3",
"Assets": "-66.0",
"Property, Plant and Equipment, Net": "-17.8",
"Assets, Current": "-42.4",
"Assets, Non-Current": "-19.2",
"Other Assets": "15.5",
"Other Expenses": "-110",
"Expenses": "-90.9",
"Revenues": "69.9",
"Net Income": "2.46",
"General and Administrative Expense": "0.961",
"Research and Development": "20.1",
"Other Revenues": "69.9",
"Other Net Income": "7.69",
"Comprehensive Net Income": "2.63",
"Economic Capital Ratio": "-27.4"
},
"2011": {
"Liabilities, Current": "21.5",
"Liabilities": "26.5",
"Stockholders Equity": "-120",
"ECR before LimitedLiability": "12.3",
"Liabilities, Non-Current": "15.7",
"Other Liabilities": "19.3",
"Property, Plant and Equipment, Net": "-28.7",
"Assets": "-95.4",
"Assets, Non-Current": "-15.7",
"Goodwill": "-40.1",
"Assets, Current": "-73.9",
"General and Administrative Expense": "19.8",
"Expenses": "-80.7",
"Revenues": "66.1",
"Net Income": "25.7",
"Research and Development": "21.0",
"Other Expenses": "-141",
"Other Revenues": "66.1",
"Comprehensive Net Income": "25.8",
"Other Net Income": "-23.1",
"Economic Capital Ratio": "-49.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001056358_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "64,485",
"Assets, Non-Current": "2,503",
"General and Administrative Expense": "116,810",
"Goodwill": "0",
"Liabilities, Current": "42,679",
"Liabilities, Non-Current": "3,348",
"Other Assets": "8,170",
"Other Compr. Net Income": "0",
"Other Expenses": "191,782",
"Other Liabilities": "4,991",
"Other Net Income": "1,519",
"Other Revenues": "289,705",
"Property, Plant and Equipment, Net": "27,144",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "51,018",
"Assets": "102,302",
"Expenses": "308,592",
"Revenues": "289,705",
"Stockholders Equity": "51,284",
"Net Income": "-17,368",
"Comprehensive Net Income": "-17,368",
"BaseVar": "376,568",
"ECR before LimitedLiability": "69%",
"Economic Capital Ratio": "145%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "55,215",
"Assets, Non-Current": "3,054",
"General and Administrative Expense": "95,411",
"Goodwill": "0",
"Liabilities, Current": "32,240",
"Liabilities, Non-Current": "4,996",
"Other Assets": "4,705",
"Other Compr. Net Income": "0",
"Other Expenses": "143,734",
"Other Liabilities": "3,107",
"Other Net Income": "441",
"Other Revenues": "228,088",
"Property, Plant and Equipment, Net": "18,449",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "40,343",
"Assets": "81,423",
"Expenses": "239,145",
"Revenues": "228,088",
"Stockholders Equity": "41,080",
"Net Income": "-10,616",
"Comprehensive Net Income": "-10,616",
"BaseVar": "294,720",
"ECR before LimitedLiability": "75%",
"Economic Capital Ratio": "150%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "41,731",
"Assets, Non-Current": "2,815",
"General and Administrative Expense": "86,118",
"Goodwill": "0",
"Liabilities, Current": "29,876",
"Liabilities, Non-Current": "5,382",
"Other Assets": "4,158",
"Other Compr. Net Income": "881",
"Other Expenses": "134,241",
"Other Liabilities": "1,359",
"Other Net Income": "-989",
"Other Revenues": "200,689",
"Property, Plant and Equipment, Net": "9,566",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "36,617",
"Assets": "58,270",
"Expenses": "220,359",
"Revenues": "200,689",
"Stockholders Equity": "21,653",
"Net Income": "-20,659",
"Comprehensive Net Income": "-20,218",
"BaseVar": "258,902",
"ECR before LimitedLiability": "20%",
"Economic Capital Ratio": "104%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 1.0379642673135412,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001056358.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001056358.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001056358.svg"
},
{
"company_id": "0001402785",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001402785.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001402785.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001402785_main_keyfigs.svg",
"name": "Fluoropharma Medical INC",
"rank": 30,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001402785.svg",
"report_text": "The relative strengths and weaknesses of Fluoropharma Medical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fluoropharma Medical INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Fluoropharma Medical INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 132% points.
The company's Economic Capital Ratio, given in the ranking table, is 85%, being 69% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001402785_2012_Fluoropharma_Medical_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "1.82",
"Liabilities": "4.56",
"Stockholders Equity": "28.6",
"Liabilities, Non-Current": "0.407",
"Other Liabilities": "0.441",
"Property, Plant and Equipment, Net": "-10.6",
"Assets": "19.8",
"Assets, Non-Current": "-7.25",
"Goodwill": "-15.2",
"Assets, Current": "56.9",
"General and Administrative Expense": "-16.4",
"Expenses": "-30.0",
"Revenues": "-68.1",
"Net Income": "-132",
"Research and Development": "-8.94",
"Other Expenses": "-0.0203",
"Other Revenues": "-68.1",
"ECR before LimitedLiability": "-6.86",
"Comprehensive Net Income": "-132",
"Other Net Income": "-49.6",
"Economic Capital Ratio": "-68.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001402785_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,315",
"Assets, Non-Current": "0",
"General and Administrative Expense": "2,075",
"Goodwill": "61",
"Liabilities, Current": "380",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "724",
"Other Liabilities": "0",
"Other Net Income": "-966",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "170",
"Research and Development": "641"
},
"output_variables": {
"Liabilities": "380",
"Assets": "3,546",
"Expenses": "3,440",
"Revenues": "0",
"Stockholders Equity": "3,166",
"Net Income": "-4,405",
"Comprehensive Net Income": "-4,405",
"BaseVar": "4,166",
"ECR before LimitedLiability": "-3.5%",
"Economic Capital Ratio": "85%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8460582571191243,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001402785.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001402785.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001402785.svg"
},
{
"company_id": "0000926617",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000926617.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000926617.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000926617.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000926617_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000926617_main_keyfigs.svg",
"name": "Aspira Women s Health Inc",
"rank": 31,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000926617.svg",
"report_text": "The relative strengths and weaknesses of Aspira Women s Health Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aspira Women s Health Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points.The greatest weakness of Aspira Women s Health Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 40% points.
The company's Economic Capital Ratio, given in the ranking table, is 84%, being 70% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000926617_2012_Aspira_Women_s_Health_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-27.4",
"Liabilities": "-16.5",
"Stockholders Equity": "1.22",
"Liabilities, Non-Current": "0.717",
"Other Liabilities": "0.0331",
"Property, Plant and Equipment, Net": "-0.750",
"Assets": "10.6",
"Assets, Non-Current": "-0.512",
"Goodwill": "-0.750",
"Assets, Current": "38.8",
"General and Administrative Expense": "-0.698",
"Expenses": "-0.271",
"Revenues": "-30.5",
"Net Income": "-40.2",
"Research and Development": "-0.703",
"Other Expenses": "3.05",
"Other Revenues": "-30.5",
"ECR before LimitedLiability": "-7.59",
"Comprehensive Net Income": "-40.3",
"Other Net Income": "-0.448",
"Economic Capital Ratio": "-69.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000926617_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "22,893",
"Assets, Non-Current": "2.0",
"General and Administrative Expense": "14,177",
"Goodwill": "0",
"Liabilities, Current": "11,476",
"Liabilities, Non-Current": "52",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "114",
"Other Liabilities": "1,224",
"Other Net Income": "-35",
"Other Revenues": "1,923",
"Property, Plant and Equipment, Net": "216",
"Research and Development": "5,387"
},
"output_variables": {
"Liabilities": "12,752",
"Assets": "23,111",
"Expenses": "19,678",
"Revenues": "1,923",
"Stockholders Equity": "10,359",
"Net Income": "-17,790",
"Comprehensive Net Income": "-17,790",
"BaseVar": "28,750",
"ECR before LimitedLiability": "-20%",
"Economic Capital Ratio": "84%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8387457462117764,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000926617.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000926617.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000926617.svg"
},
{
"company_id": "0001124608",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001124608.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001124608.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001124608_main_keyfigs.svg",
"name": "Response Genetics INC",
"rank": 32,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001124608.svg",
"report_text": "The relative strengths and weaknesses of Response Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Response Genetics INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 43% points.The greatest weakness of Response Genetics INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 80%, being 73% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001124608_2012_Response_Genetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "1.79",
"Liabilities": "9.81",
"Stockholders Equity": "-95.2",
"ECR before LimitedLiability": "-11.1",
"Liabilities, Non-Current": "4.13",
"Other Liabilities": "3.61",
"Property, Plant and Equipment, Net": "-4.13",
"Assets": "-84.7",
"Assets, Non-Current": "-3.38",
"Goodwill": "-7.94",
"Assets, Current": "-44.1",
"General and Administrative Expense": "-121",
"Expenses": "-49.9",
"Revenues": "42.8",
"Net Income": "4.93",
"Research and Development": "5.29",
"Other Expenses": "20.1",
"Other Revenues": "42.8",
"Comprehensive Net Income": "4.76",
"Other Net Income": "-2.86",
"Economic Capital Ratio": "-73.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001124608_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,739",
"Assets, Non-Current": "0",
"General and Administrative Expense": "27,003",
"Goodwill": "44",
"Liabilities, Current": "5,893",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-73",
"Other Expenses": "21",
"Other Liabilities": "241",
"Other Net Income": "0.15",
"Other Revenues": "22,643",
"Property, Plant and Equipment, Net": "1,068",
"Research and Development": "1,322"
},
"output_variables": {
"Liabilities": "6,134",
"Assets": "7,851",
"Expenses": "28,345",
"Revenues": "22,643",
"Stockholders Equity": "1,717",
"Net Income": "-5,702",
"Comprehensive Net Income": "-5,739",
"BaseVar": "32,523",
"ECR before LimitedLiability": "-48%",
"Economic Capital Ratio": "80%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8032910511337092,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001124608.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001124608.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001124608.svg"
},
{
"company_id": "0001346526",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001346526.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001346526.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001346526_main_keyfigs.svg",
"name": "ESP Resources Inc",
"rank": 33,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001346526.svg",
"report_text": "The relative strengths and weaknesses of ESP Resources Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ESP Resources Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 13% points.The greatest weakness of ESP Resources Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 80%, being 73% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001346526_2012_ESP_Resources_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-2.56",
"Liabilities": "-1.37",
"Stockholders Equity": "-58.1",
"ECR before LimitedLiability": "-11.5",
"Liabilities, Non-Current": "-0.571",
"Other Liabilities": "2.04",
"Property, Plant and Equipment, Net": "4.93",
"Assets": "-38.8",
"Assets, Non-Current": "-2.53",
"Goodwill": "-4.31",
"Assets, Current": "-19.5",
"General and Administrative Expense": "-2.27",
"Expenses": "-4.23",
"Revenues": "13.0",
"Net Income": "0.449",
"Research and Development": "6.35",
"Other Expenses": "-4.66",
"Other Revenues": "13.0",
"Comprehensive Net Income": "0.428",
"Other Net Income": "-2.27",
"Economic Capital Ratio": "-73.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001346526_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,172",
"Assets, Non-Current": "50",
"General and Administrative Expense": "8,927",
"Goodwill": "0",
"Liabilities, Current": "4,886",
"Liabilities, Non-Current": "1,032",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "6,460",
"Other Liabilities": "248",
"Other Net Income": "-71",
"Other Revenues": "11,132",
"Property, Plant and Equipment, Net": "2,690",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "6,165",
"Assets": "6,912",
"Expenses": "15,387",
"Revenues": "11,132",
"Stockholders Equity": "747",
"Net Income": "-4,326",
"Comprehensive Net Income": "-4,326",
"BaseVar": "19,834",
"ECR before LimitedLiability": "-50%",
"Economic Capital Ratio": "80%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.7996573782364719,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001346526.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001346526.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001346526.svg"
},
{
"company_id": "0001386570",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001386570.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001386570.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001386570.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001386570_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001386570_main_keyfigs.svg",
"name": "Niagen Bioscience Inc",
"rank": 34,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001386570.svg",
"report_text": "The relative strengths and weaknesses of Niagen Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Niagen Bioscience Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 18% points.The greatest weakness of Niagen Bioscience Inc is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 102% points.
The company's Economic Capital Ratio, given in the ranking table, is 73%, being 80% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001386570_2012_Niagen_Bioscience_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities": "7.56",
"Stockholders Equity": "-10.8",
"ECR before LimitedLiability": "-18.3",
"Liabilities, Non-Current": "3.72",
"Other Liabilities": "3.91",
"Property, Plant and Equipment, Net": "-3.30",
"Assets": "-28.5",
"Assets, Non-Current": "-4.22",
"Other Assets": "-0.678",
"Goodwill": "-8.77",
"Assets, Current": "-9.16",
"General and Administrative Expense": "-102",
"Expenses": "-30.9",
"Revenues": "9.52",
"Net Income": "-15.5",
"Research and Development": "9.81",
"Other Expenses": "17.7",
"Other Revenues": "9.52",
"Comprehensive Net Income": "-15.6",
"Other Net Income": "-3.94",
"Economic Capital Ratio": "-80.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001386570_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,953",
"Assets, Non-Current": "144",
"General and Administrative Expense": "15,977",
"Goodwill": "100",
"Liabilities, Current": "3,343",
"Liabilities, Non-Current": "0",
"Other Assets": "-100",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-31",
"Other Revenues": "8,113",
"Property, Plant and Equipment, Net": "1,172",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,343",
"Assets": "6,270",
"Expenses": "15,977",
"Revenues": "8,113",
"Stockholders Equity": "2,927",
"Net Income": "-7,895",
"Comprehensive Net Income": "-7,895",
"BaseVar": "16,867",
"ECR before LimitedLiability": "-81%",
"Economic Capital Ratio": "73%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.731913015062583,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001386570.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001386570.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001386570.svg"
},
{
"company_id": "0000776008",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000776008.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000776008.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000776008_main_keyfigs.svg",
"name": "ROCK Creek Pharmaceuticals INC",
"rank": 35,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000776008.svg",
"report_text": "The relative strengths and weaknesses of ROCK Creek Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ROCK Creek Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 7.1% points.The greatest weakness of ROCK Creek Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 91% points.
The company's Economic Capital Ratio, given in the ranking table, is 34%, being 120% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000776008_2012_ROCK_Creek_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "1.21",
"Liabilities": "1.48",
"Stockholders Equity": "-2.23",
"ECR before LimitedLiability": "-57.6",
"Liabilities, Non-Current": "-1.04",
"Other Liabilities": "1.22",
"Property, Plant and Equipment, Net": "-4.08",
"Assets": "-14.2",
"Assets, Non-Current": "-7.37",
"Other Assets": "2.79",
"Goodwill": "-12.7",
"Assets, Current": "7.11",
"General and Administrative Expense": "-46.9",
"Expenses": "-44.2",
"Revenues": "-29.8",
"Net Income": "-90.7",
"Other Expenses": "4.72",
"Other Revenues": "-29.8",
"Comprehensive Net Income": "-90.8",
"Other Net Income": "-4.28",
"Economic Capital Ratio": "-120"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000776008_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,734",
"Assets, Non-Current": "0",
"General and Administrative Expense": "32,748",
"Goodwill": "578",
"Liabilities, Current": "5,156",
"Liabilities, Non-Current": "2,530",
"Other Assets": "418",
"Other Compr. Net Income": "0",
"Other Expenses": "3,402",
"Other Liabilities": "0",
"Other Net Income": "-222",
"Other Revenues": "1,732",
"Property, Plant and Equipment, Net": "2,347",
"Research and Development": "3,348"
},
"output_variables": {
"Liabilities": "7,686",
"Assets": "17,077",
"Expenses": "39,498",
"Revenues": "1,732",
"Stockholders Equity": "9,391",
"Net Income": "-37,988",
"Comprehensive Net Income": "-37,988",
"BaseVar": "33,108",
"ECR before LimitedLiability": "-203%",
"Economic Capital Ratio": "34%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.33899402389574473,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000776008.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000776008.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000776008.svg"
},
{
"company_id": "0001037649",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001037649.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001037649.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001037649_main_keyfigs.svg",
"name": "Interleukin Genetics INC",
"rank": 36,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001037649.svg",
"report_text": "The relative strengths and weaknesses of Interleukin Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Interleukin Genetics INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 5.8% points.The greatest weakness of Interleukin Genetics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 70% points.
The company's Economic Capital Ratio, given in the ranking table, is 24%, being 130% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001037649_2012_Interleukin_Genetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-21.5",
"Liabilities": "-15.3",
"Stockholders Equity": "-69.9",
"ECR before LimitedLiability": "-67.6",
"Liabilities, Non-Current": "0.297",
"Other Liabilities": "0.312",
"Property, Plant and Equipment, Net": "-7.69",
"Assets": "-38.3",
"Assets, Non-Current": "-3.79",
"Other Assets": "0.180",
"Goodwill": "-5.10",
"Assets, Current": "-24.4",
"General and Administrative Expense": "-1.64",
"Expenses": "4.32",
"Revenues": "-8.30",
"Net Income": "-5.77",
"Other Expenses": "5.82",
"Other Revenues": "-8.30",
"Comprehensive Net Income": "-5.79",
"Other Net Income": "-2.47",
"Economic Capital Ratio": "-130"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001037649_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,112",
"Assets, Non-Current": "38",
"General and Administrative Expense": "6,193",
"Goodwill": "515",
"Liabilities, Current": "14,377",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "115",
"Other Liabilities": "0",
"Other Net Income": "-198",
"Other Revenues": "2,857",
"Property, Plant and Equipment, Net": "289",
"Research and Development": "1,376"
},
"output_variables": {
"Liabilities": "14,377",
"Assets": "2,954",
"Expenses": "7,684",
"Revenues": "2,857",
"Stockholders Equity": "-11,423",
"Net Income": "-5,025",
"Comprehensive Net Income": "-5,025",
"BaseVar": "14,035",
"ECR before LimitedLiability": "-239%",
"Economic Capital Ratio": "24%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.23882831282480887,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001037649.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001037649.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001037649.svg"
},
{
"company_id": "0001310630",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001310630.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001310630.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001310630_main_keyfigs.svg",
"name": "China Foods Holdings Ltd",
"rank": 37,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001310630.svg",
"report_text": "The relative strengths and weaknesses of China Foods Holdings Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Foods Holdings Ltd compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 11% points.The greatest weakness of China Foods Holdings Ltd is the variable Stockholders Equity, reducing the Economic Capital Ratio by 72% points.
The company's Economic Capital Ratio, given in the ranking table, is 20%, being 134% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001310630_2012_China_Foods_Holdings_Ltd.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-1.06",
"Liabilities": "-11.5",
"Stockholders Equity": "-72.1",
"ECR before LimitedLiability": "-71.8",
"Other Liabilities": "-4.85",
"Property, Plant and Equipment, Net": "-6.95",
"Assets": "-31.4",
"Assets, Non-Current": "-2.82",
"Other Assets": "11.4",
"Goodwill": "-6.35",
"Assets, Current": "-29.3",
"General and Administrative Expense": "3.53",
"Expenses": "7.12",
"Revenues": "-12.4",
"Net Income": "-3.76",
"Research and Development": "2.47",
"Other Expenses": "1.83",
"Other Revenues": "-12.4",
"Comprehensive Net Income": "-3.78",
"Other Net Income": "-1.24",
"Economic Capital Ratio": "-134"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001310630_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "14",
"Goodwill": "0",
"Liabilities, Current": "29",
"Liabilities, Non-Current": "0",
"Other Assets": "10.0",
"Other Compr. Net Income": "0",
"Other Expenses": "5.1",
"Other Liabilities": "50",
"Other Net Income": "0",
"Other Revenues": "0.050",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "79",
"Assets": "10.0",
"Expenses": "19",
"Revenues": "0.050",
"Stockholders Equity": "-69",
"Net Income": "-19",
"Comprehensive Net Income": "-19",
"BaseVar": "54",
"ECR before LimitedLiability": "-256%",
"Economic Capital Ratio": "20%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.196641857405686,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001310630.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001310630.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001310630.svg"
},
{
"company_id": "0001119643",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001119643.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001119643.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001119643.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001119643_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001119643_main_keyfigs.svg",
"name": "Nutra Pharma CORP",
"rank": 38,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001119643.svg",
"report_text": "The relative strengths and weaknesses of Nutra Pharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nutra Pharma CORP compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.99% points.The greatest weakness of Nutra Pharma CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.99%, being 152% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001119643_2012_Nutra_Pharma_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.986",
"Liabilities": "0.985",
"Stockholders Equity": "-61.8",
"ECR before LimitedLiability": "-90.5",
"Liabilities, Non-Current": "-0.154",
"Other Liabilities": "-0.163",
"Property, Plant and Equipment, Net": "-1.79",
"Assets": "-37.7",
"Assets, Non-Current": "-0.615",
"Goodwill": "-1.93",
"Assets, Current": "-18.4",
"General and Administrative Expense": "-4.49",
"Expenses": "-2.65",
"Revenues": "-2.80",
"Net Income": "-11.7",
"Research and Development": "0.266",
"Other Expenses": "0.176",
"Other Revenues": "-2.80",
"Comprehensive Net Income": "-11.7",
"Other Net Income": "-0.221",
"Economic Capital Ratio": "-152"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001119643_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "158",
"Assets, Non-Current": "17",
"General and Administrative Expense": "3,919",
"Goodwill": "0",
"Liabilities, Current": "4,112",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "524",
"Other Liabilities": "0",
"Other Net Income": "-23",
"Other Revenues": "160",
"Property, Plant and Equipment, Net": "55",
"Research and Development": "91"
},
"output_variables": {
"Liabilities": "4,112",
"Assets": "229",
"Expenses": "4,534",
"Revenues": "160",
"Stockholders Equity": "-3,883",
"Net Income": "-4,397",
"Comprehensive Net Income": "-4,397",
"BaseVar": "4,529",
"ECR before LimitedLiability": "-448%",
"Economic Capital Ratio": "0.99%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.00985585879676098,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001119643.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001119643.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001119643.svg"
},
{
"company_id": "0001134765",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0001134765.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0001134765.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001134765.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001134765_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001134765_main_keyfigs.svg",
"name": "Charlie s Holdings Inc",
"rank": 39,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0001134765.svg",
"report_text": "The relative strengths and weaknesses of Charlie s Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Charlie s Holdings Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.077% points.The greatest weakness of Charlie s Holdings Inc is the variable Assets, reducing the Economic Capital Ratio by 56% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.077%, being 153% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0001134765_2012_Charlie_s_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.0772",
"Liabilities": "0.0755",
"Stockholders Equity": "-37.6",
"ECR before LimitedLiability": "-91.4",
"Liabilities, Non-Current": "-0.0549",
"Other Liabilities": "-0.0251",
"Property, Plant and Equipment, Net": "-1.14",
"Assets": "-55.6",
"Assets, Non-Current": "-0.226",
"Other Assets": "0",
"Goodwill": "-0.885",
"Assets, Current": "-23.9",
"General and Administrative Expense": "-1.71",
"Expenses": "-0.811",
"Revenues": "-0.117",
"Net Income": "-11.9",
"Research and Development": "0.0474",
"Other Revenues": "-0.117",
"Comprehensive Net Income": "-11.9",
"Other Net Income": "-0.996",
"Economic Capital Ratio": "-153"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0001134765_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "238",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,369",
"Goodwill": "19",
"Liabilities, Current": "1,869",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "718",
"Other Liabilities": "103",
"Other Net Income": "-1,126",
"Other Revenues": "1,267",
"Property, Plant and Equipment, Net": "9.7",
"Research and Development": "0.29"
},
"output_variables": {
"Liabilities": "1,972",
"Assets": "267",
"Expenses": "4,087",
"Revenues": "1,267",
"Stockholders Equity": "-1,705",
"Net Income": "-3,946",
"Comprehensive Net Income": "-3,946",
"BaseVar": "4,359",
"ECR before LimitedLiability": "-561%",
"Economic Capital Ratio": "0.077%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.000772716240150905,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0001134765.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0001134765.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0001134765.svg"
},
{
"company_id": "0000880242",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000880242.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000880242.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000880242_main_keyfigs.svg",
"name": "Biolargo INC",
"rank": 40,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000880242.svg",
"report_text": "The relative strengths and weaknesses of Biolargo INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biolargo INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 0.028% points.The greatest weakness of Biolargo INC is the variable Assets, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.028%, being 153% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000880242_2012_Biolargo_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.0281",
"Liabilities": "0.0282",
"Stockholders Equity": "-18.0",
"ECR before LimitedLiability": "-91.4",
"Liabilities, Non-Current": "0.0207",
"Other Liabilities": "-0.0211",
"Property, Plant and Equipment, Net": "-0.367",
"Assets": "-31.2",
"Assets, Non-Current": "-0.0710",
"Other Assets": "0.0122",
"Goodwill": "-0.309",
"Assets, Current": "-9.59",
"General and Administrative Expense": "-1.96",
"Expenses": "-2.51",
"Revenues": "-0.342",
"Net Income": "-15.3",
"Other Expenses": "-0.0388",
"Other Revenues": "-0.342",
"Comprehensive Net Income": "-15.3",
"Other Net Income": "-0.0124",
"Economic Capital Ratio": "-153"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000880242_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "202",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,165",
"Goodwill": "0",
"Liabilities, Current": "1,374",
"Liabilities, Non-Current": "390",
"Other Assets": "42",
"Other Compr. Net Income": "0",
"Other Expenses": "846",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "156",
"Property, Plant and Equipment, Net": "2.7",
"Research and Development": "99"
},
"output_variables": {
"Liabilities": "1,764",
"Assets": "246",
"Expenses": "4,111",
"Revenues": "156",
"Stockholders Equity": "-1,518",
"Net Income": "-3,954",
"Comprehensive Net Income": "-3,954",
"BaseVar": "3,139",
"ECR before LimitedLiability": "-600%",
"Economic Capital Ratio": "0.028%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.00028210666035747184,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000880242.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000880242.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000880242.svg"
},
{
"company_id": "0000907654",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution_0000907654.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2011/graphs/IME_0000907654.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000907654.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000907654_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000907654_main_keyfigs.svg",
"name": "Oruka Therapeutics Inc",
"rank": 41,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_0000907654.svg",
"report_text": "The relative strengths and weaknesses of Oruka Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oruka Therapeutics Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 0.0000000000000000000015% points.The greatest weakness of Oruka Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 77% points.
The company's Economic Capital Ratio, given in the ranking table, is 0%, being 153% points below the market average of 153%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2011/report/0000907654_2012_Oruka_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0",
"Liabilities": "0",
"ECR before LimitedLiability": "-91.5",
"Liabilities, Non-Current": "0",
"Other Liabilities": "0",
"Property, Plant and Equipment, Net": "0",
"Assets": "-77.5",
"Stockholders Equity": "0",
"Assets, Non-Current": "0",
"Goodwill": "0",
"Assets, Current": "-23.3",
"General and Administrative Expense": "0",
"Expenses": "-50.4",
"Net Income": "-38.9",
"Research and Development": "-0.0791",
"Other Expenses": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-39.1",
"Other Net Income": "0",
"Economic Capital Ratio": "-153"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/plot_over_time/0000907654_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,212",
"Assets, Non-Current": "224",
"General and Administrative Expense": "39,356",
"Goodwill": "0",
"Liabilities, Current": "754",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "12,041",
"Other Liabilities": "16",
"Other Net Income": "27,282",
"Other Revenues": "2,026",
"Property, Plant and Equipment, Net": "66",
"Research and Development": "41,585"
},
"output_variables": {
"Liabilities": "770",
"Assets": "6,502",
"Expenses": "92,982",
"Revenues": "2,026",
"Stockholders Equity": "5,732",
"Net Income": "-63,674",
"Comprehensive Net Income": "-63,674",
"BaseVar": "64,781",
"ECR before LimitedLiability": "-1,535%",
"Economic Capital Ratio": "0.0000000000000000000015%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.5157940083916332e-23,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2011/industry_indexes/0000907654.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/equity/0000907654.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2011/analytics/profit_loss/0000907654.svg"
}
],
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_distribution/feature_distribution.svg",
"final_var_label": "Economic Capital Ratio",
"industry_box": [
[
"Revenues",
"27.2 B"
],
[
"Assets",
"31.0 B"
],
[
"Expenses",
"26.4 B"
],
[
"Stockholders Equity",
"13.2 B"
]
],
"industry_id": "us_medicinal_products",
"industry_label": "Medicinal Products",
"num_companies": 41,
"num_top_companies": 10,
"ecr_records": {
"2009": {
"0000794172": {
"rank": 1,
"ecr": "278"
},
"0000037785": {
"rank": 2,
"ecr": "225"
},
"0001056358": {
"rank": 3,
"ecr": "145"
}
},
"2010": {
"0000899923": {
"rank": 1,
"ecr": "304"
},
"0000794172": {
"rank": 2,
"ecr": "279"
},
"0000037785": {
"rank": 3,
"ecr": "209"
},
"0000874716": {
"rank": 4,
"ecr": "203"
},
"0001056358": {
"rank": 5,
"ecr": "150"
},
"0000074303": {
"rank": 6,
"ecr": "149"
},
"0001315695": {
"rank": 7,
"ecr": "132"
},
"0001145460": {
"rank": 8,
"ecr": "130"
},
"0001307954": {
"rank": 9,
"ecr": "115"
},
"0000722104": {
"rank": 10,
"ecr": "102"
}
},
"2011": {
"0000885462": {
"rank": 1,
"ecr": "287"
},
"0000899923": {
"rank": 2,
"ecr": "285"
},
"0000794172": {
"rank": 3,
"ecr": "276"
},
"0000736822": {
"rank": 4,
"ecr": "270"
},
"0000787253": {
"rank": 5,
"ecr": "256"
},
"0000711377": {
"rank": 6,
"ecr": "253"
},
"0000353569": {
"rank": 7,
"ecr": "250"
},
"0000768408": {
"rank": 8,
"ecr": "238"
},
"0000896264": {
"rank": 9,
"ecr": "235"
},
"0000811641": {
"rank": 10,
"ecr": "224"
},
"0000037785": {
"rank": 11,
"ecr": "221"
},
"0001054905": {
"rank": 12,
"ecr": "219"
},
"0001086303": {
"rank": 13,
"ecr": "216"
},
"0000810509": {
"rank": 14,
"ecr": "213"
},
"0001050007": {
"rank": 15,
"ecr": "208"
},
"0001374328": {
"rank": 16,
"ecr": "199"
},
"0000722830": {
"rank": 17,
"ecr": "183"
},
"0000874716": {
"rank": 18,
"ecr": "180"
},
"0000722104": {
"rank": 19,
"ecr": "176"
},
"0001063665": {
"rank": 20,
"ecr": "175"
},
"0001141240": {
"rank": 21,
"ecr": "168"
},
"0000074303": {
"rank": 22,
"ecr": "154"
},
"0000744218": {
"rank": 23,
"ecr": "152"
},
"0001315695": {
"rank": 24,
"ecr": "148"
},
"0001407038": {
"rank": 25,
"ecr": "146"
},
"0000949858": {
"rank": 26,
"ecr": "132"
},
"0001145460": {
"rank": 27,
"ecr": "127"
},
"0001307954": {
"rank": 28,
"ecr": "115"
},
"0001056358": {
"rank": 29,
"ecr": "104"
},
"0001402785": {
"rank": 30,
"ecr": "85"
},
"0000926617": {
"rank": 31,
"ecr": "84"
},
"0001124608": {
"rank": 32,
"ecr": "80"
},
"0001346526": {
"rank": 33,
"ecr": "80"
},
"0001386570": {
"rank": 34,
"ecr": "73"
},
"0000776008": {
"rank": 35,
"ecr": "34"
},
"0001037649": {
"rank": 36,
"ecr": "24"
},
"0001310630": {
"rank": 37,
"ecr": "20"
},
"0001119643": {
"rank": 38,
"ecr": "0.99"
},
"0001134765": {
"rank": 39,
"ecr": "0.077"
},
"0000880242": {
"rank": 40,
"ecr": "0.028"
},
"0000907654": {
"rank": 41,
"ecr": "0.0000000000000000000015"
}
}
},
"rating_box": [
[
"Top rated",
"10 of 41"
],
[
"Best, worst rating",
"287 %, < 0.001 %"
],
[
"New companies",
"31"
]
],
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2011/backtesting_correlation/regression_2011.svg",
"scentences": [
"Meridian Bioscience INC climbed -1 positions from 2 to 3 due to its excellent Liabilities.",
"Mannatech INC lost 24 positions from 5 to 29 due to its bad Stockholders Equity.",
"GULF Resources INC entered the 2012 ranking at rank 1, making it the best newcomer."
],
"url_segment": "2012-us-medicinal-products",
"year": 2012,
"feature_importance": "https://www.realrate-archive.com/us_medicinal_products/2011/feature_importance/feature_importance.svg",
"obs_ecr": {
"0000037785": {
"2011": {
"obs_EconomicCapitalRatio": 1.9637052598410045
},
"2012": {
"obs_EconomicCapitalRatio": 2.2187352745223867
},
"2013": {
"obs_EconomicCapitalRatio": 2.0998789372222704
},
"2014": {
"obs_EconomicCapitalRatio": 1.641537801830664
},
"2015": {
"obs_EconomicCapitalRatio": 1.0723385245823782
},
"2016": {
"obs_EconomicCapitalRatio": 1.6108835909734713
},
"2017": {
"obs_EconomicCapitalRatio": 1.8056499758638158
},
"2018": {
"obs_EconomicCapitalRatio": 1.2287717494570867
},
"2019": {
"obs_EconomicCapitalRatio": 1.7092843014022376
},
"2020": {
"obs_EconomicCapitalRatio": 1.9284688934634902
},
"2021": {
"obs_EconomicCapitalRatio": 1.6770740146552199
},
"2022": {
"obs_EconomicCapitalRatio": 1.834863173719622
},
"2023": {
"obs_EconomicCapitalRatio": 0.9158901623685305
}
},
"0001056358": {
"2011": {
"obs_EconomicCapitalRatio": 0.18783097649548078
},
"2012": {
"obs_EconomicCapitalRatio": 0.3196597323000155
},
"2013": {
"obs_EconomicCapitalRatio": 0.7370346023559032
},
"2014": {
"obs_EconomicCapitalRatio": 1.0406162753683343
},
"2015": {
"obs_EconomicCapitalRatio": 0.7323625964348088
},
"2016": {
"obs_EconomicCapitalRatio": 0.753066668490597
},
"2017": {
"obs_EconomicCapitalRatio": 0.5232637759318683
},
"2018": {
"obs_EconomicCapitalRatio": 0.7338326629079127
},
"2019": {
"obs_EconomicCapitalRatio": 0.6223996309643847
},
"2020": {
"obs_EconomicCapitalRatio": 0.6307022721006672
},
"2021": {
"obs_EconomicCapitalRatio": 1.4634619355072704
},
"2022": {
"obs_EconomicCapitalRatio": 0.820186420650827
},
"2023": {
"obs_EconomicCapitalRatio": 0.42412588511273297
},
"2024": {
"obs_EconomicCapitalRatio": 0.6963642400059836
},
"2025": {
"obs_EconomicCapitalRatio": 0.47545840734858463
}
},
"0000074303": {
"2011": {
"obs_EconomicCapitalRatio": 0.5221628155371295
},
"2012": {
"obs_EconomicCapitalRatio": 0.5016941351915414
},
"2013": {
"obs_EconomicCapitalRatio": 0.7067485666124749
},
"2014": {
"obs_EconomicCapitalRatio": 0.5800072775923082
},
"2015": {
"obs_EconomicCapitalRatio": 0.26932516949788865
},
"2016": {
"obs_EconomicCapitalRatio": 0.4320388824657905
},
"2017": {
"obs_EconomicCapitalRatio": 0.5856850809511247
},
"2018": {
"obs_EconomicCapitalRatio": 0.3494568183316394
},
"2019": {
"obs_EconomicCapitalRatio": 0.2952768225185927
},
"2020": {
"obs_EconomicCapitalRatio": 0.48260038439530095
},
"2021": {
"obs_EconomicCapitalRatio": 1.1559183950584917
},
"2022": {
"obs_EconomicCapitalRatio": 0.9955682298738215
},
"2023": {
"obs_EconomicCapitalRatio": 0.939616887252673
},
"2024": {
"obs_EconomicCapitalRatio": 0.5703504787209263
},
"2025": {
"obs_EconomicCapitalRatio": 0.3659536949506686
}
},
"0001307954": {
"2011": {
"obs_EconomicCapitalRatio": 0.18938003655153654
},
"2012": {
"obs_EconomicCapitalRatio": 0.3154058367754545
},
"2013": {
"obs_EconomicCapitalRatio": 0.4780017903384275
},
"2014": {
"obs_EconomicCapitalRatio": 0.384792729924332
},
"2018": {
"obs_EconomicCapitalRatio": 0.5095392164405845
},
"2019": {
"obs_EconomicCapitalRatio": 0.6235372978487372
},
"2020": {
"obs_EconomicCapitalRatio": 0.6619386066086855
},
"2021": {
"obs_EconomicCapitalRatio": 0.8463350886179348
},
"2022": {
"obs_EconomicCapitalRatio": 0.7115101902118032
},
"2023": {
"obs_EconomicCapitalRatio": 0.7137373813546445
},
"2024": {
"obs_EconomicCapitalRatio": 0.5244746605193847
},
"2025": {
"obs_EconomicCapitalRatio": 0.3141640811372542
}
},
"0000874716": {
"2011": {
"obs_EconomicCapitalRatio": 5.678189619495421
},
"2012": {
"obs_EconomicCapitalRatio": 6.62985272864075
},
"2013": {
"obs_EconomicCapitalRatio": 5.637583008591172
},
"2014": {
"obs_EconomicCapitalRatio": 5.3378472038789315
},
"2015": {
"obs_EconomicCapitalRatio": 4.359021798706142
},
"2016": {
"obs_EconomicCapitalRatio": 6.735635676724686
},
"2017": {
"obs_EconomicCapitalRatio": 7.882744231502931
},
"2018": {
"obs_EconomicCapitalRatio": 10.363928250251758
},
"2019": {
"obs_EconomicCapitalRatio": 12.865202087427075
},
"2020": {
"obs_EconomicCapitalRatio": 21.31825222425334
},
"2021": {
"obs_EconomicCapitalRatio": 26.268423294328166
},
"2022": {
"obs_EconomicCapitalRatio": 13.828898358817076
},
"2023": {
"obs_EconomicCapitalRatio": 18.252894151087883
},
"2024": {
"obs_EconomicCapitalRatio": 13.560026821642062
},
"2025": {
"obs_EconomicCapitalRatio": 21.570882602865723
}
},
"0000899923": {
"2011": {
"obs_EconomicCapitalRatio": 5.286603114326388
},
"2012": {
"obs_EconomicCapitalRatio": 5.947932077650038
},
"2013": {
"obs_EconomicCapitalRatio": 4.09378437010731
},
"2014": {
"obs_EconomicCapitalRatio": 5.490507086553531
},
"2015": {
"obs_EconomicCapitalRatio": 6.944372988710795
},
"2016": {
"obs_EconomicCapitalRatio": 2.339757271124506
},
"2017": {
"obs_EconomicCapitalRatio": 2.8740508316547966
},
"2018": {
"obs_EconomicCapitalRatio": 3.0914586906825567
},
"2019": {
"obs_EconomicCapitalRatio": 1.9630081673133826
},
"2021": {
"obs_EconomicCapitalRatio": 2.606632146369483
},
"2022": {
"obs_EconomicCapitalRatio": 1.7004450020894173
},
"2023": {
"obs_EconomicCapitalRatio": 2.215290054291016
},
"2024": {
"obs_EconomicCapitalRatio": 1.823931615329854
},
"2025": {
"obs_EconomicCapitalRatio": 1.1682929523136367
}
},
"0000885462": {
"2011": {
"obs_EconomicCapitalRatio": 0.477594589877508
},
"2012": {
"obs_EconomicCapitalRatio": 0.2925556156090612
},
"2013": {
"obs_EconomicCapitalRatio": 0.5361327962905387
},
"2014": {
"obs_EconomicCapitalRatio": 0.2505281175819798
},
"2015": {
"obs_EconomicCapitalRatio": 0.43387267254203915
},
"2016": {
"obs_EconomicCapitalRatio": 0.5022902813318385
},
"2017": {
"obs_EconomicCapitalRatio": 0.34065719753844165
},
"2018": {
"obs_EconomicCapitalRatio": 0.22997496410238202
},
"2019": {
"obs_EconomicCapitalRatio": 0.1659154208060553
},
"2020": {
"obs_EconomicCapitalRatio": 0.26901950354979465
},
"2021": {
"obs_EconomicCapitalRatio": 0.2838385361778253
},
"2022": {
"obs_EconomicCapitalRatio": 0.2067987843408893
},
"2023": {
"obs_EconomicCapitalRatio": 0.11983703427943283
},
"2024": {
"obs_EconomicCapitalRatio": 0.06649192725741328
}
},
"0001054905": {
"2011": {
"obs_EconomicCapitalRatio": 1.4579074706215878
},
"2012": {
"obs_EconomicCapitalRatio": 1.7997149963883579
},
"2013": {
"obs_EconomicCapitalRatio": 1.964317914289097
},
"2014": {
"obs_EconomicCapitalRatio": 1.4734327096252018
},
"2015": {
"obs_EconomicCapitalRatio": 1.8591617658964918
},
"2016": {
"obs_EconomicCapitalRatio": 2.185789648905985
},
"2017": {
"obs_EconomicCapitalRatio": 1.7880006703658458
},
"2018": {
"obs_EconomicCapitalRatio": 1.5318875768219857
},
"2019": {
"obs_EconomicCapitalRatio": 2.6164701172132556
},
"2020": {
"obs_EconomicCapitalRatio": 2.4715120247319406
},
"2021": {
"obs_EconomicCapitalRatio": 2.201354917056966
},
"2022": {
"obs_EconomicCapitalRatio": 2.262740511238834
}
},
"0001141240": {
"2011": {
"obs_EconomicCapitalRatio": 5.502360615827963
},
"2012": {
"obs_EconomicCapitalRatio": 2.4369547526522646
},
"2013": {
"obs_EconomicCapitalRatio": 11.581935819020808
},
"2014": {
"obs_EconomicCapitalRatio": 7.5454875670319685
},
"2015": {
"obs_EconomicCapitalRatio": 5.634514556207966
},
"2016": {
"obs_EconomicCapitalRatio": 5.458003060729301
},
"2017": {
"obs_EconomicCapitalRatio": 6.7960569922086025
},
"2018": {
"obs_EconomicCapitalRatio": 4.351678898468258
},
"2019": {
"obs_EconomicCapitalRatio": 4.24355658618375
},
"2020": {
"obs_EconomicCapitalRatio": 3.6370684560423614
},
"2021": {
"obs_EconomicCapitalRatio": 4.458556769073509
},
"2022": {
"obs_EconomicCapitalRatio": 3.1784879275692157
},
"2023": {
"obs_EconomicCapitalRatio": 3.3273144132655075
},
"2024": {
"obs_EconomicCapitalRatio": 2.3178398698599603
},
"2025": {
"obs_EconomicCapitalRatio": 5.890984282760348
}
},
"0000768408": {
"2011": {
"obs_EconomicCapitalRatio": 5.715133312847765
},
"2012": {
"obs_EconomicCapitalRatio": 2.3017018284798714
},
"2013": {
"obs_EconomicCapitalRatio": 1.425277475641039
},
"2014": {
"obs_EconomicCapitalRatio": 1.8803973873475237
},
"2015": {
"obs_EconomicCapitalRatio": 1.4412650279511978
},
"2016": {
"obs_EconomicCapitalRatio": 1.0071551396713583
},
"2017": {
"obs_EconomicCapitalRatio": 1.1153169457297638
},
"2018": {
"obs_EconomicCapitalRatio": 0.924011890899123
},
"2019": {
"obs_EconomicCapitalRatio": 0.6138635192851674
},
"2020": {
"obs_EconomicCapitalRatio": 0.7664774974857526
},
"2021": {
"obs_EconomicCapitalRatio": 0.871286208388657
},
"2022": {
"obs_EconomicCapitalRatio": 0.27420450138403873
},
"2023": {
"obs_EconomicCapitalRatio": 0.26934082796065434
},
"2024": {
"obs_EconomicCapitalRatio": 0.14158948221183076
}
},
"0000787253": {
"2011": {
"obs_EconomicCapitalRatio": 2.526353775920534
},
"2012": {
"obs_EconomicCapitalRatio": 1.3160543270878733
},
"2014": {
"obs_EconomicCapitalRatio": 1.1960142220158665
},
"2015": {
"obs_EconomicCapitalRatio": 2.1497060764213507
},
"2016": {
"obs_EconomicCapitalRatio": 1.6596075035664513
},
"2017": {
"obs_EconomicCapitalRatio": 1.820275172276164
},
"2018": {
"obs_EconomicCapitalRatio": 1.4250126839098163
},
"2019": {
"obs_EconomicCapitalRatio": 0.8714870157425864
},
"2020": {
"obs_EconomicCapitalRatio": 0.8186963761612863
},
"2021": {
"obs_EconomicCapitalRatio": 0.9963355986876283
},
"2022": {
"obs_EconomicCapitalRatio": 0.4935946735445941
},
"2023": {
"obs_EconomicCapitalRatio": 0.4463203114259345
},
"2024": {
"obs_EconomicCapitalRatio": 0.21764563032603712
}
},
"0000896264": {
"2011": {
"obs_EconomicCapitalRatio": 2.987080353491173
},
"2012": {
"obs_EconomicCapitalRatio": 2.8476111068826424
},
"2013": {
"obs_EconomicCapitalRatio": 4.5724271596679005
},
"2015": {
"obs_EconomicCapitalRatio": 7.320772852461824
},
"2016": {
"obs_EconomicCapitalRatio": 2.5202405198959905
},
"2017": {
"obs_EconomicCapitalRatio": 5.400078197143357
},
"2018": {
"obs_EconomicCapitalRatio": 7.8437625855710635
},
"2019": {
"obs_EconomicCapitalRatio": 5.208661448534275
},
"2022": {
"obs_EconomicCapitalRatio": 2.794889038132937
},
"2023": {
"obs_EconomicCapitalRatio": 2.6884992698433976
},
"2024": {
"obs_EconomicCapitalRatio": 1.4865583930571376
}
},
"0001086303": {
"2012": {
"obs_EconomicCapitalRatio": 0.050408616621473605
},
"2013": {
"obs_EconomicCapitalRatio": 0.3592188918384183
},
"2014": {
"obs_EconomicCapitalRatio": 0.5202291430401021
},
"2018": {
"obs_EconomicCapitalRatio": 75.60385532024324
},
"2023": {
"obs_EconomicCapitalRatio": 5.825073650532234
}
},
"0001134765": {
"2013": {
"obs_EconomicCapitalRatio": 84.83868255676903
},
"2014": {
"obs_EconomicCapitalRatio": 93.1111485713505
},
"2015": {
"obs_EconomicCapitalRatio": 199.2672351710133
},
"2016": {
"obs_EconomicCapitalRatio": 216.93321071912177
},
"2017": {
"obs_EconomicCapitalRatio": 60.02178473917171
},
"2018": {
"obs_EconomicCapitalRatio": 12.822507944414118
},
"2019": {
"obs_EconomicCapitalRatio": 455.3649181791688
},
"2020": {
"obs_EconomicCapitalRatio": 668.0565240083155
},
"2021": {
"obs_EconomicCapitalRatio": 3.604592501252785
},
"2022": {
"obs_EconomicCapitalRatio": 3.9983823737615998
},
"2023": {
"obs_EconomicCapitalRatio": 4.432317616137024
},
"2024": {
"obs_EconomicCapitalRatio": 2.934393508015559
},
"2025": {
"obs_EconomicCapitalRatio": 7.17941906968866
}
},
"0001310630": {
"2011": {
"obs_EconomicCapitalRatio": 118.5920894437218
},
"2012": {
"obs_EconomicCapitalRatio": 90.47339849409984
},
"2013": {
"obs_EconomicCapitalRatio": 72.75975087344283
},
"2014": {
"obs_EconomicCapitalRatio": 60.05301282758653
},
"2015": {
"obs_EconomicCapitalRatio": 46.147679617159916
},
"2016": {
"obs_EconomicCapitalRatio": 37.04924725418156
},
"2017": {
"obs_EconomicCapitalRatio": 30.944660874575487
},
"2019": {
"obs_EconomicCapitalRatio": 85.1712892994052
},
"2020": {
"obs_EconomicCapitalRatio": 24.70852870017063
},
"2023": {
"obs_EconomicCapitalRatio": 90.31718007058653
},
"2024": {
"obs_EconomicCapitalRatio": 18.12427183566627
},
"2025": {
"obs_EconomicCapitalRatio": 15.788052734849284
}
},
"0001374328": {
"2011": {
"obs_EconomicCapitalRatio": 1.843040104492836
},
"2012": {
"obs_EconomicCapitalRatio": 1.406513180725925
},
"2013": {
"obs_EconomicCapitalRatio": 2.5629155706742086
},
"2014": {
"obs_EconomicCapitalRatio": 3.2200542353297674
},
"2015": {
"obs_EconomicCapitalRatio": 1.2965403490667224
},
"2016": {
"obs_EconomicCapitalRatio": 0.9353195843240845
},
"2017": {
"obs_EconomicCapitalRatio": 0.4394415225694401
},
"2018": {
"obs_EconomicCapitalRatio": 0.9423630321081906
},
"2019": {
"obs_EconomicCapitalRatio": 2.6565609559613317
},
"2020": {
"obs_EconomicCapitalRatio": 9.948498907383927
},
"2022": {
"obs_EconomicCapitalRatio": 4.994024545393992
},
"2023": {
"obs_EconomicCapitalRatio": 2.2965761578523303
},
"2024": {
"obs_EconomicCapitalRatio": 3.6843422189586965
},
"2025": {
"obs_EconomicCapitalRatio": 1.821523711080343
}
},
"0001386570": {
"2011": {
"obs_EconomicCapitalRatio": 8.338141326290996
},
"2012": {
"obs_EconomicCapitalRatio": 8.392729648541112
},
"2013": {
"obs_EconomicCapitalRatio": 26.219216155099797
},
"2019": {
"obs_EconomicCapitalRatio": 8.591985092140105
},
"2020": {
"obs_EconomicCapitalRatio": 10.063615397839953
},
"2021": {
"obs_EconomicCapitalRatio": 6.442513704241379
},
"2022": {
"obs_EconomicCapitalRatio": 2.8215640716473835
},
"2023": {
"obs_EconomicCapitalRatio": 2.6556157143776864
},
"2024": {
"obs_EconomicCapitalRatio": 9.237391489557004
},
"2025": {
"obs_EconomicCapitalRatio": 7.630478708487693
}
},
"0000711377": {
"2011": {
"obs_EconomicCapitalRatio": 5.820904874555574
},
"2012": {
"obs_EconomicCapitalRatio": 7.7503288458074415
},
"2013": {
"obs_EconomicCapitalRatio": 10.377788751403328
},
"2014": {
"obs_EconomicCapitalRatio": 9.392743252183534
},
"2015": {
"obs_EconomicCapitalRatio": 10.034849829461312
},
"2016": {
"obs_EconomicCapitalRatio": 10.103194801881472
},
"2017": {
"obs_EconomicCapitalRatio": 14.452119850474038
},
"2018": {
"obs_EconomicCapitalRatio": 8.566992718065048
},
"2019": {
"obs_EconomicCapitalRatio": 9.17563055998759
},
"2020": {
"obs_EconomicCapitalRatio": 9.88631712937769
},
"2021": {
"obs_EconomicCapitalRatio": 9.735723882656965
},
"2022": {
"obs_EconomicCapitalRatio": 5.856026588966056
}
},
"0000744218": {
"2011": {
"obs_EconomicCapitalRatio": 1.8965131603685095
},
"2012": {
"obs_EconomicCapitalRatio": 5.333855573956268
},
"2013": {
"obs_EconomicCapitalRatio": 10.230725112264693
},
"2014": {
"obs_EconomicCapitalRatio": 11.553522232787866
},
"2015": {
"obs_EconomicCapitalRatio": 8.22074780222265
},
"2016": {
"obs_EconomicCapitalRatio": 1.4980547705405713
},
"2017": {
"obs_EconomicCapitalRatio": 2.021188969442516
},
"2018": {
"obs_EconomicCapitalRatio": 0.3696518300152486
},
"2019": {
"obs_EconomicCapitalRatio": 0.48016381910130834
},
"2020": {
"obs_EconomicCapitalRatio": 5.262656817463394
},
"2021": {
"obs_EconomicCapitalRatio": 7.793666490988671
},
"2022": {
"obs_EconomicCapitalRatio": 10.883731101898258
},
"2023": {
"obs_EconomicCapitalRatio": 7.286143405813059
}
},
"0000811641": {
"2011": {
"obs_EconomicCapitalRatio": 2.136690390726703
},
"2012": {
"obs_EconomicCapitalRatio": 1.849039798017059
},
"2013": {
"obs_EconomicCapitalRatio": 2.010189247495304
},
"2014": {
"obs_EconomicCapitalRatio": 2.34474040567545
},
"2015": {
"obs_EconomicCapitalRatio": 2.4785461696903734
},
"2016": {
"obs_EconomicCapitalRatio": 1.9865134449583703
},
"2017": {
"obs_EconomicCapitalRatio": 1.6949100276813254
},
"2018": {
"obs_EconomicCapitalRatio": 1.7852801061870174
},
"2019": {
"obs_EconomicCapitalRatio": 1.5240857269328754
},
"2020": {
"obs_EconomicCapitalRatio": 1.7195565413895542
},
"2021": {
"obs_EconomicCapitalRatio": 2.367024189117178
},
"2022": {
"obs_EconomicCapitalRatio": 1.6292353884860042
},
"2023": {
"obs_EconomicCapitalRatio": 1.1622002191801761
},
"2025": {
"obs_EconomicCapitalRatio": 1.9024392280197613
}
},
"0000907654": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 2.2151696375266194
},
"2014": {
"obs_EconomicCapitalRatio": 1.8158262418443614
},
"2015": {
"obs_EconomicCapitalRatio": 1.28497308211443
},
"2016": {
"obs_EconomicCapitalRatio": 1.0818389503384735
},
"2017": {
"obs_EconomicCapitalRatio": 1.3032495591532267
},
"2018": {
"obs_EconomicCapitalRatio": 0.6794655548784231
},
"2019": {
"obs_EconomicCapitalRatio": 1.027889384231902
},
"2020": {
"obs_EconomicCapitalRatio": 0.7572061787169263
},
"2021": {
"obs_EconomicCapitalRatio": 0.6116995115921646
},
"2022": {
"obs_EconomicCapitalRatio": 0.8326777832489594
}
},
"0000926617": {
"2011": {
"obs_EconomicCapitalRatio": 0.936747166508658
},
"2012": {
"obs_EconomicCapitalRatio": 3.2987773210340476
},
"2013": {
"obs_EconomicCapitalRatio": 3.310250104657181
},
"2014": {
"obs_EconomicCapitalRatio": 4.317801092124128
},
"2015": {
"obs_EconomicCapitalRatio": 7.655824111431128
},
"2016": {
"obs_EconomicCapitalRatio": 8.900428301796273
},
"2017": {
"obs_EconomicCapitalRatio": 20.503758003717643
},
"2018": {
"obs_EconomicCapitalRatio": 3.2888488055796508
},
"2019": {
"obs_EconomicCapitalRatio": 8.83333842031845
},
"2020": {
"obs_EconomicCapitalRatio": 45.47327065656971
},
"2021": {
"obs_EconomicCapitalRatio": 7.933579854593867
},
"2022": {
"obs_EconomicCapitalRatio": 2.857163597552752
},
"2023": {
"obs_EconomicCapitalRatio": 3.901740100848714
},
"2024": {
"obs_EconomicCapitalRatio": 1.8703748454852225
}
},
"0000949858": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 2.518997627887442
},
"2018": {
"obs_EconomicCapitalRatio": 0.7422482465262066
},
"2019": {
"obs_EconomicCapitalRatio": 0.35343147435010663
},
"2020": {
"obs_EconomicCapitalRatio": 1.3239430629183255
},
"2021": {
"obs_EconomicCapitalRatio": 2.1718168400927897
},
"2022": {
"obs_EconomicCapitalRatio": 0.9346116862802668
}
},
"0000009326": {
"2012": {
"obs_EconomicCapitalRatio": 5.656587982913678
},
"2013": {
"obs_EconomicCapitalRatio": 7.79966708407013
},
"2014": {
"obs_EconomicCapitalRatio": 2.9084764827636236
},
"2015": {
"obs_EconomicCapitalRatio": 2.8483648673741246
},
"2016": {
"obs_EconomicCapitalRatio": 3.648755401436501
},
"2017": {
"obs_EconomicCapitalRatio": 3.787889348418163
},
"2019": {
"obs_EconomicCapitalRatio": 4.035821822778718
},
"2020": {
"obs_EconomicCapitalRatio": 4.735832660774467
},
"2021": {
"obs_EconomicCapitalRatio": 6.878840843345401
},
"2022": {
"obs_EconomicCapitalRatio": 3.32579266803479
},
"2023": {
"obs_EconomicCapitalRatio": 4.327515096253764
},
"2024": {
"obs_EconomicCapitalRatio": 5.341740174720832
},
"2025": {
"obs_EconomicCapitalRatio": 4.797400698850301
}
},
"0000073290": {
"2012": {
"obs_EconomicCapitalRatio": 1.8838244732270972
},
"2013": {
"obs_EconomicCapitalRatio": 1.6432390281123206
},
"2014": {
"obs_EconomicCapitalRatio": 1.9239557658497293
},
"2015": {
"obs_EconomicCapitalRatio": 2.669474942212977
},
"2016": {
"obs_EconomicCapitalRatio": 5.686234008415378
},
"2017": {
"obs_EconomicCapitalRatio": 12.426535116483144
},
"2018": {
"obs_EconomicCapitalRatio": 6.023112230267755
},
"2019": {
"obs_EconomicCapitalRatio": 8.71810270966778
},
"2020": {
"obs_EconomicCapitalRatio": 5.758603861413226
},
"2021": {
"obs_EconomicCapitalRatio": 7.171288908839465
},
"2022": {
"obs_EconomicCapitalRatio": 6.5820905271862715
},
"2023": {
"obs_EconomicCapitalRatio": 2.3689702399551757
},
"2024": {
"obs_EconomicCapitalRatio": 0.8328246370864223
}
},
"0000093314": {
"2012": {
"obs_EconomicCapitalRatio": 17.719277991697727
},
"2013": {
"obs_EconomicCapitalRatio": 16.172791954794842
},
"2014": {
"obs_EconomicCapitalRatio": 17.12412941207431
},
"2015": {
"obs_EconomicCapitalRatio": 17.094853012648368
},
"2016": {
"obs_EconomicCapitalRatio": 7.646119704869701
},
"2017": {
"obs_EconomicCapitalRatio": 7.835630820870826
},
"2018": {
"obs_EconomicCapitalRatio": 5.69389490958303
},
"2020": {
"obs_EconomicCapitalRatio": 10.494231213006202
},
"2021": {
"obs_EconomicCapitalRatio": 9.325363829987609
},
"2022": {
"obs_EconomicCapitalRatio": 7.038632118707036
},
"2023": {
"obs_EconomicCapitalRatio": 1.692739776873626
},
"2024": {
"obs_EconomicCapitalRatio": 2.538095829463765
},
"2025": {
"obs_EconomicCapitalRatio": 1.267911014322384
}
},
"0001504678": {
"2021": {
"obs_EconomicCapitalRatio": 21.761860501462678
},
"2023": {
"obs_EconomicCapitalRatio": 7.712264043121101
},
"2024": {
"obs_EconomicCapitalRatio": 4.273885183694472
}
},
"0001321834": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.25079529133050554
},
"2025": {
"obs_EconomicCapitalRatio": 0.6661650116856921
}
},
"0001627223": {
"2015": {
"obs_EconomicCapitalRatio": 0.11531512461593406
},
"2016": {
"obs_EconomicCapitalRatio": 0.5041107353269599
},
"2017": {
"obs_EconomicCapitalRatio": 0.9792616137942283
},
"2018": {
"obs_EconomicCapitalRatio": 0.5037929444305274
},
"2019": {
"obs_EconomicCapitalRatio": 0.33457321143007535
},
"2020": {
"obs_EconomicCapitalRatio": 0.5470460275521768
},
"2021": {
"obs_EconomicCapitalRatio": 0.6499364328629865
},
"2022": {
"obs_EconomicCapitalRatio": 0.5809502304277893
}
},
"0001552189": {
"2022": {
"obs_EconomicCapitalRatio": 0.051966645127577905
},
"2023": {
"obs_EconomicCapitalRatio": 0.16744960403999323
}
},
"0001653477": {
"2016": {
"obs_EconomicCapitalRatio": 2.9965230053381644
},
"2017": {
"obs_EconomicCapitalRatio": 3.7915367442390675
},
"2018": {
"obs_EconomicCapitalRatio": 2.922808947052789
},
"2019": {
"obs_EconomicCapitalRatio": 1.959253575073628
},
"2020": {
"obs_EconomicCapitalRatio": 1.5143708031469667
},
"2021": {
"obs_EconomicCapitalRatio": 1.3249257731828572
},
"2022": {
"obs_EconomicCapitalRatio": 1.1004777222391815
},
"2023": {
"obs_EconomicCapitalRatio": 0.7369191018660393
},
"2024": {
"obs_EconomicCapitalRatio": 0.7736223011953498
},
"2025": {
"obs_EconomicCapitalRatio": 1.3076730606119293
}
},
"0001586554": {
"2016": {
"obs_EconomicCapitalRatio": 0.48058259081278015
},
"2018": {
"obs_EconomicCapitalRatio": 1.4962619054091728
},
"2019": {
"obs_EconomicCapitalRatio": 0.891464023479221
},
"2020": {
"obs_EconomicCapitalRatio": 0.5424015614406267
},
"2021": {
"obs_EconomicCapitalRatio": 0.4143393157324369
},
"2022": {
"obs_EconomicCapitalRatio": 0.23894685685583492
},
"2023": {
"obs_EconomicCapitalRatio": 0.10261033505859418
}
},
"0001642380": {
"2016": {
"obs_EconomicCapitalRatio": 21.72207919293821
},
"2017": {
"obs_EconomicCapitalRatio": 21.3709545386487
},
"2019": {
"obs_EconomicCapitalRatio": 4.529546805842379
},
"2021": {
"obs_EconomicCapitalRatio": 1.6309746744371012
},
"2022": {
"obs_EconomicCapitalRatio": 0.4521509520900019
},
"2023": {
"obs_EconomicCapitalRatio": 0.3591924761920325
}
},
"0001652130": {
"2016": {
"obs_EconomicCapitalRatio": 3.199958649296
},
"2017": {
"obs_EconomicCapitalRatio": 3.3067347442937
},
"2018": {
"obs_EconomicCapitalRatio": 2.957402513032481
},
"2019": {
"obs_EconomicCapitalRatio": 4.091879539456148
},
"2020": {
"obs_EconomicCapitalRatio": 9.369785151591545
},
"2021": {
"obs_EconomicCapitalRatio": 12.780171311702386
},
"2022": {
"obs_EconomicCapitalRatio": 3.4031614469183005
}
},
"0001708035": {
"2017": {
"obs_EconomicCapitalRatio": 0.4391634781975079
},
"2018": {
"obs_EconomicCapitalRatio": 0.3838203482983531
},
"2019": {
"obs_EconomicCapitalRatio": 0.48129649674893044
},
"2020": {
"obs_EconomicCapitalRatio": 0.6013288369758395
},
"2021": {
"obs_EconomicCapitalRatio": 0.8978665871292398
},
"2022": {
"obs_EconomicCapitalRatio": 0.7567918532035208
},
"2023": {
"obs_EconomicCapitalRatio": 0.7709750516345434
},
"2024": {
"obs_EconomicCapitalRatio": 0.6033738356189466
},
"2025": {
"obs_EconomicCapitalRatio": 1.152367959333189
}
},
"0001522767": {
"2017": {
"obs_EconomicCapitalRatio": 4.28352597297854
},
"2018": {
"obs_EconomicCapitalRatio": 11.84484946199016
},
"2019": {
"obs_EconomicCapitalRatio": 1.6647152363257145
},
"2020": {
"obs_EconomicCapitalRatio": 1.8939909944990796
},
"2023": {
"obs_EconomicCapitalRatio": 0.7154614969958419
},
"2024": {
"obs_EconomicCapitalRatio": 0.2730915686403338
},
"2025": {
"obs_EconomicCapitalRatio": 0.22748336782703915
}
},
"0001731348": {
"2020": {
"obs_EconomicCapitalRatio": 1.0343902967287055
},
"2021": {
"obs_EconomicCapitalRatio": 0.9151944120269997
},
"2022": {
"obs_EconomicCapitalRatio": 0.5292237994678327
},
"2023": {
"obs_EconomicCapitalRatio": 0.5873188828335296
},
"2024": {
"obs_EconomicCapitalRatio": 0.48595324362468467
}
},
"0001656472": {
"2020": {
"obs_EconomicCapitalRatio": 2.4846037628909143
},
"2021": {
"obs_EconomicCapitalRatio": 2.1068641047612973
},
"2022": {
"obs_EconomicCapitalRatio": 1.5226433295914465
},
"2023": {
"obs_EconomicCapitalRatio": 1.2617458734917226
},
"2024": {
"obs_EconomicCapitalRatio": 1.2298351104750205
},
"2025": {
"obs_EconomicCapitalRatio": 1.6798919218022832
}
},
"0001737927": {
"2020": {
"obs_EconomicCapitalRatio": 2.2413009969523126
},
"2021": {
"obs_EconomicCapitalRatio": 0.722105723732089
},
"2022": {
"obs_EconomicCapitalRatio": 0.49880311487341555
}
},
"0001754195": {
"2025": {
"obs_EconomicCapitalRatio": 0.6572335792654658
}
},
"0001756390": {
"2021": {
"obs_EconomicCapitalRatio": 1.6656381745552173
},
"2022": {
"obs_EconomicCapitalRatio": 0.2766604451340951
},
"2023": {
"obs_EconomicCapitalRatio": 0.2521606213881799
},
"2024": {
"obs_EconomicCapitalRatio": 0.09670274277596863
},
"2025": {
"obs_EconomicCapitalRatio": 0.15693027900478207
}
},
"0001813814": {
"2022": {
"obs_EconomicCapitalRatio": 1.017428702644666
}
},
"0001850902": {
"2021": {
"obs_EconomicCapitalRatio": 5.898441690535421
},
"2022": {
"obs_EconomicCapitalRatio": 1.4117684980890728
}
},
"0001906324": {
"2022": {
"obs_EconomicCapitalRatio": 3.794104483895451
},
"2023": {
"obs_EconomicCapitalRatio": 0.8130511823271402
},
"2024": {
"obs_EconomicCapitalRatio": 0.6055538968322262
},
"2025": {
"obs_EconomicCapitalRatio": 0.4114130862644389
}
}
}
}